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If people were meant to pop out of bed in the morning, we would all sleep in 
toasters 
(Author unknown, attributed to Jim Davis, Garfield) 
 
 
If you think you are too small to make a difference, try sleeping with a 
mosquito in the room 
         (Dalai Lama XIV) 
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ABSTRACT 
 
Sleep and wakefulness are regulated by an intricate interplay of multiple systems originating 
in the brainstem, hypothalamus, and basal forebrain (BF) that are under both circadian and 
homeostatic control. The circadian regulation is important for the timing of sleep, and the 
homeostatic regulation drives the intensity of sleep, based on the duration and quality of 
preceding wakefulness. The ascending arousal systems mediate their effects on wakefulness 
and cortical activity via a thalamic and an extrathalamic route. The extrathalamic route 
through  the  BF  sends  projections  to  the  entire  brain  and  could  be  involved  in  sleep  
homeostasis, because during prolonged wakefulness or sleep deprivation (SD), the 
extracellular build-up of adenosine specifically inhibits cholinergic neurons of the BF.  
In this thesis I explored the role of the ascending arousal systems in the regulation of sleep, 
wakefulness, and cortical activation mediated by the BF. Polysomnographic recordings with 
or without combined in vivo microdialysis in freely behaving animals were used, to test the 
following hypotheses: During SD, the ascending arousal systems increase their activity to 
counteract the effects of increased sleep pressure. Increased activity of the ascending 
arousal systems increases BF activity during SD and results in a homeostatic sleep response. 
The  actions  of  the  ascending  arousal  systems  are,  in  the  BF,  mediated  by  cholinergic  
neurons.  
The results show that overexpression of orexin leads to minor changes in vigilance state 
distribution, and to increased slow wave intrusions during prolonged wakefulness. During 
SD, the extracellular levels of serotonin and dopamine metabolites increased gradually, 
reaching a plateau from the third hour of SD. In contrast, extracellular BF histamine levels 
increased immediately when SD started and remained at the same level throughout the six 
hour SD, returning back to baseline immediately afterwards. On the baseline day, 
extracellular histamine levels showed a strong correlation with the amount of wakefulness, 
during both the light and the dark period. Although during wakefulness all studied 
ascending arousal systems increased their transmitter release in the BF, not all of them 
seem to be involved in the regulation of sleep homeostasis. The orexinergic, serotonergic, 
and dopaminergic systems show signs that they are involved in the regulation of sleep 
pressure, or at least that they are affected by sleep homeostasis. The increased sleepiness 
of mice overexpressing orexin might indicate that the orexinergic system is capable of 
influencing sleep homeostasis. The gradual increase in dopamine and serotonin turnover in 
the BF during SD shows that those transmitter systems are affected by increased sleep 
pressure,  and  they  might  counteract  sleep  pressure  or  add  to  it.  On  the  other  hand,  
histamine release in the BF is not affected by sleep pressure, and histamine perfusion into 
the BF does not result in a homeostatic response, showing that the histaminergic system is 
9 
 
neither affected by nor able to manipulate sleep pressure in the BF, and thus shows no signs 
of being involved in sleep homeostasis mediated by the BF.  
Histamine perfusion into the BF led to theta-enriched cortical arousal, which did not result 
in a homeostatic sleep response. Because perfusion of other excitatory transmitters into the 
BF  did  induce  a  homeostatic  response,  the  type  of  activation  of  the  BF  neurons  might  be  
crucial to result in the build-up of sleep pressure, and this is most likely receptor and 
neurotransmitter specific.  
Perfusing a histamine receptor 1 antagonist into the BF resulted in a dramatic decrease in 
wakefulness and cortical arousal, demonstrating that activation of the BF by histamine 
receptor 1 is essential in sustaining wakefulness and a high level of cortical activation.  
Finally,  a  specific  neurotoxin  was  used  to  lesion  the  cholinergic  neurons  of  the  BF,  after  
which the effects of histamine and histamine receptor 1 antagonist perfusion into the BF 
were ablated, indicating the importance of the cholinergic BF in mediating the wake-
promoting effects of histamine. A lack of activation of the cholinergic BF by histamine may 
be important in initiating and maintaining NREM sleep. 
According to these results, the BF might be the main route for histamine to promote 
wakefulness,  it  might  also  be  the  main  route  for  the  other  ascending  arousal  systems  to  
promote wakefulness, however this should be further investigated. A better understanding 
of the mechanisms by which the BF is activated and mediates this activation to the cortex 
might help us to find better therapies or medications for those suffering from sleep or wake 
disorders.    
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3-MT    3-methoxytyramine 
5-HT    5-hydroxytryptamine, serotonin 
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NMDA   N-methyl-D-aspartate 
NREM sleep   non-rapid eye movement sleep 
OX1R, OX2R  orexin-1 receptor, orexin-2 receptor  
PKA    protein kinase A 
POAH    preoptic anterior hypothalamus 
PPT/LDT  pedunculopontine and laterodorsal tegmental nuclei 
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SSRI   selective serotonin re-uptake inhibitor 
SWA   slow wave activity 
TMN    tuberomammillary nucleus 
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vPAG    ventral periaqueductal gray 
VTA   ventral tegmental area 
  
12 
 
1 REVIEW OF THE LITERATURE 
 
Sleep and wakefulness are two mutually exclusive vigilance states. Sleep is a naturally 
occurring quickly reversible behavioral state of quiescence characterized by a reduced 
responsiveness to external stimuli, usually accompanied by a species-specific timing of daily 
sleep periods and typical sleep postures. Wakefulness is characterized by consciousness, 
awareness and activity. In addition to defining the vigilance states on the basis of these 
criteria, in mammals and birds sleep and wakefulness are also defined by characteristic 
electroencephalogram (EEG) and electromyogram (EMG) patterns in polysomnographic 
recordings, in which the EEG describes the electrical activity of cortical neurons and the 
EMG describes the electrical activity of muscles. 
 
1.1  Vigilance states and EEG correlates 
Based on EEG and EMG recordings, three separate vigilance states can be identified: 
wakefulness, non-rapid eye movement (NREM) sleep (also referred to as slow wave sleep), 
and rapid eye movement (REM) sleep (also known as paradoxical sleep). 
Wakefulness is characterized by low-amplitude fast activity in the EEG combined with a high 
muscle tone. At sleep onset the EEG waves will start slowing and their amplitude starts to 
increase. Sleep is divided into two distinct states: NREM and REM sleep. NREM sleep is 
defined by high-amplitude low-frequency EEG activity and decreased muscle tone. REM 
sleep is characterized by a low-amplitude desynchronized EEG and a loss of muscle tone. 
The  REM  sleep  EEG  is  very  similar  to  the  EEG  of  wakefulness,  and  therefore  the  EMG  is  
needed to distinguish the two (Fig. 1).  
Rodent sleep is polyphasic, which means that their sleep consists of periods of NREM and 
REM sleep that are interspersed with wakefulness. 
1.1.1 Wakefulness-specific EEG correlates 
In rodents, during wakefulness, the high theta range (above 7 Hz) is associated with active 
exploratory behavior and attentive wakefulness (Kramis et al.,  1975; Lancel, 1993), varying 
between 4-12 Hz depending on the animal, species, and recording method (Winson, 1972; 
van  Lier  et  al.,  2003).  The  beta  (15-30  Hz)  and  gamma  (30-60  Hz)  ranges  are  also  
prominently present in the waking EEG (reviewed in Steriade, 2006). During quiet 
wakefulness, the slower EEG frequencies become more prevalent, the delta (0.5-4 HZ) and 
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low theta (4-7 Hz) ranges being associated with increased sleep pressure and drowsiness 
during wakefulness.  
1.1.2 NREM sleep-specific EEG correlates 
Typically, during NREM sleep three main EEG patterns are present: slow oscillations (0.5-1 
Hz),  slow  waves,  also  termed  delta  waves  (1-4  Hz),  and  sleep  spindles  (12-15  Hz).  The  
amount and amplitude of the slow oscillations and slow waves is referred to as slow wave 
activity (SWA), and reflects sleep intensity. Sleep spindles are found during the lighter stages 
of  NREM  sleep  in  human  sleep  (Dijk,  2009),  and  occur  shortly  before  the  transition  from  
NREM to REM sleep in rodents (Vyazovskiy et al., 2004). 
 
Figure 1. Vigilance state-specific polysomnographic recordings  
Eight seconds of data from EEG and EMG recordings from Han-Wistar rats showing the specific 
characteristics of the three different vigilance states. 
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1.2 Regulation of wakefulness 
1.2.1 Ascending arousal systems 
Several collateral and overlapping neurotransmitter systems are involved in the promotion 
of wakefulness. Morruzi and Magoun (1949) were the first to describe the ascending 
reticular activating system, a net-like structure in the brainstem that is capable of inducing 
cortical activation. Subsequent studies showed that the neurons responsible for arousal 
were not part of the undifferentiated reticular formation, but consisted of monoaminergic 
and cholinergic neurons that reside in specific cell groups, together comprising the 
ascending arousal systems (Fig. 2; reviewed in Jones, 2003). The ascending arousal systems 
send widespread projections to the cortex via two main pathways, a dorsal pathway that is 
relayed in the thalamus, and an extrathalamic ventral route that extends through the 
hypothalamus and is conveyed to the cortex by the basal forebrain (BF; Starzl et al., 1951). 
These multiple alternative systems for promoting wakefulness are vastly interconnected and 
mutually excitatory to each other. This high level of redundancy may be necessary so that 
when one part of the system fails another can take over and maintain wakefulness.  
The monoaminergic cell groups that project to the forebrain include the noradrenergic locus 
coeruleus (LC), the serotonergic dorsal and median raphe nuclei (DRN/MRN), dopaminergic 
neurons  from  the  ventral  tegmental  area  (VTA),  substantia  nigra  (SN),  and  ventral  
periaqueductal gray (vPAG), and histaminergic neurons from the tuberomammillary nucleus 
(TMN; Dahlstrom and Fuxe, 1964; Panula et al., 1989; Kocsis et al., 2006; Lu et al., 2006). 
These cell groups send most of their projections to the cortex via the ventral pathway, while 
a  smaller  amount  of  projections  is  sent  to  the  thalamus  via  the  dorsal  route.  In  general,  
neurons  from  these  groups  fire  most  actively  during  wakefulness,  decrease  their  activity  
during  NREM  sleep,  and  stop  firing  during  REM  sleep  (Aston-Jones  and  Bloom,  1981;  
Steininger et al., 1999; Kocsis et al., 2006; Takahashi et al., 2006).  
Another part of the ascending arousal systems is a group of neurons found in the lateral 
hypothalamus (LH), containing orexin, also known as hypocretin (de Lecea et al., 1998; 
Sakurai et al., 1998). These neurons send both ascending and descending projections; they 
project to the entire cerebral cortex, as well as to the brainstem and BF, with particularly 
dense  input  to  the  TMN  and  the  LC  (Peyron  et  al.,  1998),  and  fire  predominantly  during  
wakefulness (Lee et al., 2005a; Mileykovskiy et al., 2005).  
A group of brainstem cholinergic neurons that project to the forebrain is found in the 
pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). They mainly innervate the  
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Figure 2. Ascending arousal systems and their pathways  
Schematic sagittal representation of the major neuronal systems and their main pathways involved 
in promoting wakefulness. 5-HT, 5-hydroxytryptamine (serotonin); Ach, acetylcholine; BF, basal 
forebrain; DA, dopamine; DRN/MRN, dorsal and median raphe nucei; Glu, glutamate; HA, histamine; 
LC, locus coeruleus; LH, lateral hypothalamus; NA, noradrenalin; ORX, orexin; PPT/LDT, 
pedunculopontine and laterodorsal tegmental nuclei; SN, substantia nigra; TMN, tuberomammillary 
nucleus; vPAG, ventral periaqueductal gray; VTA, ventral tegmental area. 
 
thalamus, but also the LH, BF, and prefrontal cortex (Satoh and Fibiger, 1986; Hallanger et 
al., 1987).The firing rate of PPT/LDT neurons is highest during wakefulness and REM sleep, 
and lowest during NREM sleep, suggesting that they contribute to cortical activation during 
both wakefulness and REM sleep (el Mansari et al., 1989; Steriade, 1993). Because their 
firing rate usually increases just before the transition from cortical slow waves to faster 
frequencies (Boucetta and Jones, 2009), these neurons might have an important role in the 
initiation of wakefulness and REM sleep. 
Although all of these ascending arousal systems are important in regulating wakefulness, 
only those that were studied in the original manuscripts included in this thesis will be 
introduced in detail below (Section 1.4).  
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1.2.2 The basal forebrain 
The BF consists of cholinergic, glutamatergic and GABAergic neurons that play a central role 
in regulating wakefulness and cortical arousal (Detari and Vanderwolf, 1987; Buzsaki et al., 
1988). These neurons are located in an area that extends from the medial septum/diagonal 
band of Broca (MS/DBB) to the magnocellular preoptic area (MCPO), substantia innominata 
(SI), and horizontal diagonal band of Broca (HDB). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The basal forebrain area 
Schematic coronal representation of the location of the basal forebrain (circled area). In this thesis 
the BF is defined as the cortically projecting area including the MCPO, SI,  and HDB. Coordinates at 
the  top  of  each  drawing  show  the  distance  from  bregma.  3V,  third  ventricle;  ac,  anterior  
commissure; B, basal nucleus (Meynert); cc, corpus callosum; CPu, caudate putamen; HDB, 
horizontal diagonal band of Broca; LV, lateral ventricle; MCPO, magnocellular preoptic area; MnPO, 
median preoptic area; MS, medial septum; ox, optic chiasm; SI, substantia innominata; VLPO, 
ventrolateral preoptic area. 
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The cholinergic neurons send widespread ascending projections to the cerebral cortex and 
limbic systems (Rye et al., 1984; Saper, 1984; Luiten et al., 1987); MS/DBB neurons project 
to the hippocampus, where they are involved in generating hippocampal theta (Winson, 
1978), whereas the MCPO, SI, and HDB neurons innervate the cortex and are suggested to 
modulate cortical theta activity (Lee et al., 2005b; Jones, 2008). In the studies that are 
discussed in this thesis the BF is defined as the cortically projecting area including the 
MCPO, SI, and HDB (Fig. 3). 
The BF receives input from all of the ascending arousal systems (Semba et al., 1988a; Semba 
et al., 1988b; Jones and Cuello, 1989; Panula et al., 1989; Szymusiak, 1995; Peyron et al., 
1998; Jones, 2004). In vitro studies showed that cholinergic neurons are excited by 
glutamate, noradrenalin, histamine, dopamine and orexin (Fort et al., 1995; Khateb et al., 
1995; Eggermann et al., 2001; Berlanga et al., 2005), and inhibited by serotonin (Khateb et 
al., 1993). In addition to ascending projections to the cortex, the BF neurons send 
descending projections back to the ascending arousal systems (Semba et al., 1989; 
Szymusiak, 1995). 
Recordings of BF cholinergic neurons and measurements of cortical acetylcholine (Ach) 
release  show  the  highest  activity  and  maximal  ACh  release  during  wakefulness  and  REM  
sleep. During NREM sleep, the cholinergic neurons are least active, and ACh release is low 
(Detari et al., 1999; Szymusiak et al., 2000). Activation of BF neurons with glutamate 
agonists promotes wakefulness and ACh release (Lamour et al., 1986; Manfridi et al., 1999; 
Cape and Jones, 2000; Wigren et al., 2007). On the other hand, lesions of the cholinergic 
neurons can reduce wakefulness, whereas excitotoxic lesions that kill both cholinergic and 
non-cholinergic neurons cause increased EEG delta activity (Kaur et al., 2008). Even larger 
lesions that cover most of the BF clearly reduce wakefulness (Buzsaki et al., 1988). 
A large additional population of cortically projecting BF neurons produce GABA, and a 
smaller number produce glutamate (Freund and Gulyas, 1991; Gritti et al., 1997; Hur and 
Zaborszky, 2005; Henny and Jones, 2008). GABAergic neurons, accounting for about one-
third of the cortically projecting neurons, are co-distributed with the cholinergic population 
(Gritti et al., 1997). Two physiologically distinct groups of GABAergic neurons exist; one is 
active during wakefulness, and a second group is associated with NREM sleep (Duque et al., 
2000; Manns et al., 2000; Modirrousta et al., 2004). GABAergic BF neurons innervate, and 
are thought to inhibit, cortical GABAergic interneurons and deep layer pyramidal cells 
(Freund and Meskenaite, 1992; Henny and Jones, 2008), which could result in the 
disinhibition of cortical circuits. 
These results demonstrate the importance of the BF in promoting wakefulness and suggest 
that cholinergic and non-cholinergic neurons of the BF act together to produce wakefulness 
(Szymusiak et al., 2000; Jones, 2005).  
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1.3 Sleep regulation  
Two groups of sleep-active neurons were identified in the preoptic anterior hypothalamus 
(POAH); they are located in the ventrolateral preoptic area (VLPO; Sherin et al., 1996) and 
the median preoptic area (MnPO; Suntsova et al., 2002; Gong et al., 2004; Sakai, 2011). Both 
the VLPO and MnPO send inhibitory GABAergic projections to the wake-promoting neurons 
of the ascending arousal systems, and in the VLPO neurons GABA is co-localized with galanin 
(Sherin et al., 1998; Steininger et al., 2001; Gaus et al., 2002; Suntsova et al., 2007; Uschakov 
et al., 2007). Thus, by inhibiting the ascending arousal systems, the VLPO and MnPO can 
promote NREM sleep. 
1.3.1 The two process model of sleep regulation 
Sleep is regulated by the interaction of two major biological factors that together dictate the 
timing and intensity of sleep. These factors are the homeostatic and the circadian process, 
as described in the two process model of sleep regulation (Fig. 4; Borbely, 1982; Achermann 
et  al.,  1993).  In  this  model,  the  homeostatic  process  (process  S)  increases  during  
wakefulness as sleep pressure accumulates, and decreases during sleep. The circadian 
process (process C) does not depend directly on prior sleep-wake amounts, and modulates 
the timing of sleep according to the intrinsic circadian rhythm of approximately 24 hours 
(reviewed in Takahashi et al., 2008). The intrinsic rhythm of humans is slightly longer and 
that of rodents is slightly shorter than 24 hours; it uses light to synchronize to the light-dark 
cycle of the environment. The circadian rhythm also controls many biological and 
physiological processes in the body, and is regulated at the molecular level by a 
transcriptional-translational feedback loop in the suprachiasmatic nucleus (SCN), located in 
the anterior hypothalamus (Moore and Eichler, 1972; Stephan and Zucker, 1972). 
These two processes work together in regulating the timing and intensity of sleep. The 
circadian signal promotes wakefulness during the active period, resulting in increasing 
homeostatic sleep pressure, and when the homeostatic sleep pressure reaches a critical 
level in combination with a reduction of the circadian signal, sleep is initiated.  
During prolonged wakefulness or sleep deprivation (SD) the animals are kept awake longer 
than usual, and because the sleep pressure keeps increasing during wakefulness this leads 
to additional sleep pressure, which results in a recovery sleep that is characterized by 
increased SWA and NREM sleep duration (Achermann and Borbely, 2003). 
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Figure 4. The two process model of sleep regulation (Borbely, 1982) 
Sleep is regulated by an interaction of homeostatic sleep pressure (process S) and the circadian 
rhythm (process C), leading to alternating periods of wakefulness (white areas) and sleep (black 
areas). Upper panel: During wakefulness Process S increases in a saturating exponential way. Sleep is 
initiated when Process S is high and Process C is low; when sleep is initiated Process S decreases 
exponentially. SD induces additional sleep pressure which results in increased SWA and amount of 
NREM sleep during the subsequent recovery sleep. Lower panel: The amount and the quality of 
wakefulness are important factors in the increase of Process S; when wakefulness is interrupted by 
brief sleep or slow wave intrusions during SD, part of the sleep pressure can already be relieved and 
the build-up of Process S is thus attenuated. 
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During SD, characteristic EEG patterns of NREM sleep can leak into the waking EEG. These 
intrusions of slow waves into the waking EEG during SD are thought to reflect increased 
sleep pressure or sleepiness (Cajochen et al., 2002; Leemburg et al., 2010; Van Someren, 
2010).  Slow  waves  are  usually  only  seen  during  NREM  sleep,  in  fact  they  are  the  key  
characteristic of this state and thought to be responsible for the decline of sleep pressure, 
and thus process S. When slow waves intrude into the waking EEG they can also reduce 
sleep pressure (Leemburg et al., 2010). According to the two process model of sleep, the 
strongest reduction of sleep pressure occurs at the start of NREM sleep and declines 
exponentially (Achermann et al., 1993); therefore, although these intrusions are brief, they 
may still have a substantial effect on reducing sleep pressure. 
In addition to the amount of preceding wakefulness, also the quality of wakefulness is an 
important factor in sleep pressure build-up. More exploratory behavior during wakefulness 
leads to increased SWA in the subsequent sleep period (Huber et al., 2007), and increased 
waking theta could be responsible for inducing the homeostatic response (Wigren et al., 
2007). 
1.3.2 Adenosine  
Ever since Legendre and Piéron (1910) found that the injection of cerebrospinal fluid (CSF) 
from sleep-deprived dogs induced sleep in non-deprived animals, many studies have been 
performed to find the substance responsible for this sleep-inducing effect. This so-called 
endogenous  sleep  factor  (factor  S)  should  meet  certain  criteria:  (1)  it  should  induce  and  
maintain sleep; (2) it should build up during wakefulness and prolonged wakefulness, and by 
doing so reflect sleep pressure; (3) it should increase SWA; (4) it should be eliminated during 
sleep (Borbely and Tobler, 1989). 
Evidence points to the neuromodulator adenosine as a possible mediator of the 
homeostatic sleep response. Adenosine is the end-product of ATP metabolism; when energy 
demands are high, ATP consumption exceeds its synthesis and adenosine levels increase. 
According to Benington and Heller (1995), wakefulness is a state of high energy 
consumption that depletes brain energy stores, which in turn increases sleep pressure, and 
the concentration of adenosine. NREM sleep would be responsible for restoring the brain 
energy stores resulting in a decrease in adenosine levels.  
Adenosine is a purine nucleoside that acts extracellularly on four types of G protein-coupled 
receptors (A1,  A2A,  A2B,  and  A3; Fredholm, 2010). Adenosine inhibits the actions of wake-
active neurons by binding to the A1 receptor (Benington et al., 1995; Schwierin et al., 1996; 
Basheer  et  al.,  2004;  Arrigoni  et  al.,  2006;  Liu  and  Gao,  2007),  and  the  activation  of  A2A 
receptors is thought to stimulate or disinhibit the sleep-active neurons of the VLPO 
(Scammell et al., 2001; Morairty et al., 2004; Gallopin et al., 2005; Methippara et al., 2005). 
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The intra- and extracellular levels of adenosine are regulated by several enzymes. Adenosine 
is formed from AMP by 5’-nucleotidase, and adenosine kinase phosphorylates it back into 
AMP. Because the formation of adenosine depends on the amount of AMP, and AMP is 
formed when ATP is metabolized, the rates of ATP synthesis and its metabolism are crucial 
factors in the rate of adenosine increase. Adenosine can be cleared from the extracellular 
space by diffusion through equilibrative nucleoside transporters, by formation of AMP, or it 
is metabolized into inosine by adenosine deaminase (reviewed in Porkka-Heiskanen and 
Kalinchuk, 2011). 
In addition to linking sleep regulation to neuronal activity and brain energy metabolism, 
adenosine also fulfills the criteria to be considered a sleep factor. Systemic or local 
administrations of adenosine or its receptor agonists increase NREM sleep and SWA 
(Feldberg and Sherwood, 1954; Haulica et al., 1973; Radulovacki, 1985; Ticho and 
Radulovacki, 1991; Benington et al., 1995; Satoh et al., 1996; Porkka-Heiskanen et al., 1997; 
Portas et al., 1997; Basheer et al., 1999; Porkka-Heiskanen et al., 2000), and extracellular 
adenosine levels increase during natural and prolonged wakefulness in the cholinergic BF 
and  the  cortex  (Porkka-Heiskanen  et  al.,  1997;  Porkka-Heiskanen  et  al.,  2000;  Porkka-
Heiskanen et al., 2002; McCarley, 2007). Furthermore, the most commonly used stimulant 
by humans, caffeine, promotes wakefulness by antagonizing the sleep-inducing actions of 
adenosine through the A1 and A2A receptors (Fredholm et al., 1999). 
1.3.3 Basal forebrain and sleep homeostasis  
In addition to its wake-promoting effects, the cholinergic BF plays an important role in the 
homeostatic sleep response to prolonged waking. During natural and prolonged 
wakefulness extracellular adenosine levels increase selectively in the wake-promoting BF 
area, and to a lesser extent in the cortex (Porkka-Heiskanen et al., 1997; Porkka-Heiskanen 
et al., 2000). Because adenosine levels increase due to energy consumption, which is high 
during wakefulness, and because adenosine levels increase specifically in the BF, the BF 
could have the unique possibility to keep track of the amount and the intensity of preceding 
wakefulness. And subsequently the BF could regulate the appropriate amount of recovery 
sleep.  
Adenosine inhibits cholinergic neurons and possibly also other wake-promoting neurons in 
the BF via A1 receptors (Thakkar et al., 2003; Gass et al., 2009). Selective lesioning of the BF 
cholinergic neurons with the immunotoxin 192IgG-saporin stops the increase in extracellular 
adenosine during SD (Blanco-Centurion et al., 2006; Kalinchuk et al., 2008), it reduces 
waking EEG theta (Kaur et al., 2008) and gamma (Berntson et al., 2002), and it decreases the 
homeostatic recovery sleep response (Kalinchuk et al., 2008). Unilateral perfusion of 
adenosine into the BF increased NREM sleep and delta power as well as c-Fos expression in 
both cholinergic and non-cholinergic neurons (Basheer et al., 1999). An increase in NREM 
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sleep and delta power (as seen during recovery sleep after SD) was also observed after 
perfusion of an adenosine transport inhibitor into the BF, but not when it was perfused into 
the thalamus, although it increased extracellular adenosine levels in both areas (Porkka-
Heiskanen et al., 1997). These results demonstrate that the BF is particularly susceptible to 
the actions of adenosine and that sleep might be induced by inhibiting the wake-promoting 
cholinergic BF neurons.  
What mechanisms underlie these site-specific actions of adenosine is unclear. Since SD does 
not affect the activity of enzymes that mediate adenosine metabolism (Alanko et al., 2003; 
Mackiewicz et al., 2003), increases in extracellular adenosine levels in the BF are most likely 
either the result of increased intracellular or extracellular ATP metabolism, or of decreased 
transporter activity.  A recent study suggested that not the cholinergic neurons, but instead 
astrocytes might be the source of extracellular adenosine (Halassa et al., 2009). They found 
a decrease in SWA and in the amount of recovery sleep following SD in genetically 
engineered mice with inhibited gliotransmission, which prevents ATP release from 
astrocytes. Because antagonizing the A1 receptor did not show any effect in these mice, they 
propose that ATP release from astrocytes modulates the accumulation of sleep pressure via 
a pathway that involves the A1 receptor.  
1.3.4 The “flip-flop” switch 
The transitions between wakefulness and sleep are suggested to be controlled by the “flip-
flop”  switch  (Saper  et  al.,  2001;  Saper  et  al.,  2005).  This  model  incorporates  the  fact  that  
under normal physiological conditions transitions between vigilance states are fast and well-
defined, and is based on the mutually inhibitory interactions between the sleep-promoting 
neurons of the VLPO and the wake-promoting monoaminergic transmitters of the ascending 
arousal systems (McGinty and Szymusiak, 2000; Saper et al., 2001).  
Activity of the monoaminergic ascending arousal systems inhibits the VLPO and activates 
the cortex, which leads to wakefulness (Gallopin et al., 2000; Liu et al., 2010). During sleep 
the VLPO inhibits the monoaminergic ascending arousal systems by direct GABAergic and 
galaninergic projections (Gervasoni et al., 1998; Sherin et al., 1998). Thus, via reciprocal 
inhibition each group inhibits the activity of the other, removing the inhibition onto itself, 
and thereby indirectly reinforcing its own activity.  
Orexin may be able to stabilize the flip-flop switch, because it influences both sides. During 
wakefulness orexin increases the activity of the monoaminergic neurons, and thus indirectly 
promotes inhibition of the VLPO. When orexin neurons become less active, and thus lift the 
inhibition on the VLPO, this results in a strong suppression of all the ascending arousal 
systems. The strongest evidence for orexin stabilizing sleep/wake states came from the 
observation that the orexinergic system is impaired in narcolepsy, a sleep disorder 
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characterized by behavioral state instability (McGinty and Szymusiak, 2000; Saper et al., 
2001). 
Under conditions of high sleep pressure, models of the flip-flop switch show signs of 
instability (Fulcher et al., 2010), which might explain why we observe micro-sleeps and slow 
wave intrusions in the EEG of animals and humans during SD. 
 
1.4 The ascending arousal systems in detail 
1.4.1 Orexin 
Orexinergic system, projections, and innervation 
Orexin was discovered simultaneously by two independent research groups (de Lecea et al., 
1998; Sakurai et al., 1998). Because this newly discovered peptide increases food 
consumption in rats, one group named it orexin after the Greek word for appetite, orexis 
(Sakurai et al., 1998). The other group gave the peptide the name hypocretin, combining the 
names of the location where the peptide was synthesized (hypothalamus), and the hormone 
secretin, which structure the peptide resembled (de Lecea et al., 1998). The name orexin is 
used throughout this thesis.     
Orexin is produced by orexinergic neurons, a rather small population of neuronal cells 
located in the perifornical area of the LH (de Lecea et al., 1998; Sakurai et al., 1998). Orexin 
neurons send ascending projections to the midline hypothalamic nuclei, the lateral preoptic 
area,  the BF,  and to the cortex.  They also project  to the LC,  TMN, DRN/MRN, VTA,  SI,  and 
PPT/LDT (Peyron et al., 1998; Date et al., 1999; Saper et al., 2005). 
Orexin neurons receive afferents from many components of sleep/wake related systems, 
including the BF, LC, DRN/MRN, VLPO, amygdala, infralimbic cortex, nucleus accumbens 
shell, preoptic area, lateral septum, and the bed nucleus of the stria terminalis (Sakurai et 
al., 2005; Yoshida et al., 2006). 
Synthesis and metabolism of orexin 
The precursor peptide prepro-orexin is proteolytically cleaved to form orexin A and orexin B. 
The peptides are packaged in dense core vesicles and are most likely synaptically released 
(Fig. 5; de Lecea et al., 1998; Sakurai et al., 1998). 
Receptors  
There are two known orexin receptors, the orexin-1 receptor (OX1R) and the orexin-2 
receptor (OX2R), both of which are G protein-coupled receptors with excitatory effects. 
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Figure 5. Orexinergic neurotransmission 
The precursor peptide prepro-orexin is proteolytically cleaved to form orexin A and orexin B. They 
are packaged in dense core vesicles and most likely synaptically released into the synaptic cleft 
where they bind to OX1R or OX2R. OX1R, orexin-1 receptor; OX2R, orexin-2 receptor. 
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Although it  is  known that  orexin receptor activation leads to a Ca2+ influx, the responsible 
mechanisms  in  neurons  have  not  been  well  established  (Sakurai  et  al.,  1998).  The  OX1R  
shows a 10-fold higher affinity for binding orexin A, while the OX2R binds both isoforms with 
equal affinity. The orexinergic receptors show very distinct expression patterns. OX1R is 
found in the hippocampus, LC, and the anterior part of the hypothalamus near the SCN. The 
OX2R is mostly found in the TMN, LH, paraventricular nucleus, arcuate nucleus, amygdala, 
bed nucleus of the stria terminalis, and nucleus accumbens. Both receptors are expressed in 
the cortex, BF, DRN/MRN, VTA, and PPT/LDT (Trivedi et al., 1998; Lu et al., 2000; Marcus et 
al., 2001). 
The orexinergic system in sleep-wake regulation   
The first indication of the involvement of orexin in sleep-wake regulation was observed by 
Lin et al (1999), when they discovered that a mutation in the OX2R gene causes narcolepsy 
in dogs. Narcolepsy is a sleep disorder that is characterized by excessive daytime sleepiness 
and sleep fragmentation. Some patients suffer from cataplexy, a sudden weakening of the 
muscle tone that is usually triggered by emotional stimuli. Since this first discovery, many 
studies have found evidence which links the orexinergic system to narcolepsy (reviewed in 
Sakurai et al., 2010).   
Orexin neurons are active during wakefulness and silent during NREM and REM sleep (Lee et 
al., 2005a; Mileykovskiy et al., 2005; Sakurai et al., 2010). Intracerebroventricular injection 
of  orexin  A  or  orexin  B  in  rats  increases  the  amount  of  wakefulness  and  decreases  NREM  
and REM sleep (Hagan et al., 1999; Piper et al., 2000; Huang et al., 2001). Recently, 
optogenetic studies demonstrated that the orexin neurons are capable of inducing arousal 
from sleep (Adamantidis et al., 2007; Carter et al., 2009). Selective destruction of the orexin 
neurons induces symptoms of narcolepsy (Hara et al., 2001), similar as in orexin or orexin 
receptor knockouts (Chemelli et al., 1999). Compared to double knockouts, OX2R-knockout 
mice exhibit a less severe narcoleptic phenotype, while OX1R-knockout mice show only a 
mild fragmentation of sleep and wake states, without cataplexy (Willie et al., 2003; Sakurai 
et al., 2010). In addition, preliminary results from chronic overexpression of orexin in mice 
showed suppression of REM sleep during the light period and fragmented NREM sleep 
(Mieda et al., 2004).  
Orexin is proposed to be involved in stabilizing the wake-state in the “flip-flop” switch 
(McGinty and Szymusiak, 2000; Saper et al., 2001). A recently described positive feedback 
loop shows that orexin neurons are able to activate themselves both directly and indirectly 
(via orexin-activated glutaminergic neurons) through OX2R. This mechanism might serve to 
maintain the activity of orexin neurons during wakefulness (Yamanaka et al., 2010), and 
enable them to activate the ascending arousal systems. 
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Orexin has an excitatory effect on cholinergic BF neurons, presumably through OX2R 
(Eggermann et al., 2001), and infusion of orexin into the BF increases wakefulness (Espana 
et al., 2001; Thakkar et al., 2001). The orexinergic system appears to be under the control of 
sleep homeostasis, because optogenetic stimulation after SD resulted less frequently in an 
arousal from NREM sleep (Carter et al., 2009). 
1.4.2 Serotonin 
Serotonergic system, projections, and innervation 
Serotonergic projections innervate nearly all regions of the brain. Ascending pathways 
originate primarily in the DRN/MRN, while descending pathways innervating the spinal cord 
originate from the nucleus raphe magnus, pallidus, and obscurus (Dahlstrom and Fuxe, 
1964). 
The DRN/MRN send ascending projections to the BF, SN, VTA, MS/DBB, hypothalamus, and 
nucleus accumbens (Semba et al., 1988b; Tork, 1990). In addition, the DRN projects to the 
frontal cortex, striatum, and the ventral hippocampus, and the MRN projects to the 
cingulate cortex and hippocampus (Lorens and Guldberg, 1974; Geyer et al., 1976; Azmitia 
and Segal, 1978; McQuade and Sharp, 1997; Vertes et al., 1999; Kusljic and Van Den Buuse, 
2012). 
The  DRN/MRN  receive  projections  from  the  BF,  LC,  SN,  vPAG,  VTA,  LH,  and  the  medial  
prefrontal cortex (Marcinkiewicz et al., 1989; Behzadi et al., 1990; Hajos et al., 1998; Peyron 
et al., 1998). 
Synthesis and metabolism of serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) is synthesized from L-tryptophan. L-tryptophan is 
hydroxylated by tryptophan hydroxylase to form 5-hydroxy-tryptophan, which is 
subsequently decarboxylated by amino acid decarboxylase to form serotonin. Until it is 
released, serotonin is stored in synaptic vesicles, which protect the molecules from 
catabolizing enzymes. The activity of serotonin in the synapse is mainly terminated by its re-
uptake into the presynaptic terminal by the serotonin transporter (SERT; Fig. 6).  
Serotonin is metabolized by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetic acid 
(5-HIAA), which is the main metabolite of serotonin in the brain. The extracellular 
concentration of 5-HIAA is much higher than that of serotonin; in the rat brain about 1000 
times. Two forms of MAO have been identified: MAO-A preferentially deaminates serotonin 
and norepinephrine, whereas MAO-B exhibits the highest affinity for ?-phenylethylamine 
and dopamine (reviewed in Adell et al., 2002). 
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Figure 6. Serotonergic neurotransmission 
Serotonin is synthesized in two steps from L-tryptophan and is stored in vesicles until released. It 
acts though seven main families of receptors and can be actively taken up by the serotonin 
transporter.  Intra-  or  extracellularly  serotonin  is  metabolized  into  5-HIAA  by  MAO-A.  5-HIAA,  5-
hydroxyindoleacetic acid; 5-HT, serotonin; MAO-A, monoamine oxidase A; SERT, serotonin 
transporter. 
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Receptors 
Seven main families of serotonin receptors (5-HT1-7) have been identified, comprising in total 
14  subtypes,  with  five  subtypes  of  the  5-HT1 receptor  (a,  b,  d,  e,  f),  three  5-HT2 receptor 
subtypes (a-c), and two types of 5-HT5 receptors (a and b).  
Serotonin receptors mediate their effect through G protein-coupled second messenger 
systems, with the exception of the 5-HT3 receptor, which is a ligand-gated ion channel. The 
5-HT1 and 5-HT5 receptor families have an inhibitory effect through G protein-coupled 
inhibition of adenylyl cyclase and subsequently cyclic adenosine monophosphate (cAMP). 
5-HT2 receptors are coupled to G proteins that increase the hydrolysis of inositol phosphates 
and elevate cytosolic Ca2+ levels,  thus  having  an  excitatory  effect.  The  5-HT3 receptor 
triggers rapid depolarization due to a transient inward current, subsequent to the opening 
of nonselective cation channels (Na+, Ca2+ influx). The response desensitizes rapidly. The 5-
HT4,6,7 receptor families all have excitatory effects through G protein-coupled stimulation of 
adenylyl cyclase and cAMP. cAMP causes activation of protein kinase A (PKA), which in turn 
activates other important signalling molecules.  5-HT1a receptors are expressed throughout 
the brain. In the raphe nuclei, they are somatodendritic and act as autoreceptors to inhibit 
cell firing. 
Postsynaptic 5-HT1a receptors are located in a number of limbic structures, particularly the 
hippocampus. 5-HT1b receptor expression is concentrated in the basal ganglia, striatum and 
frontal cortex, where they are thought to serve as autoreceptors. In addition, this receptor 
may act as a heteroreceptor controlling the release of other neurotransmitters, such as ACh, 
glutamate, dopamine, noradrenalin, and GABA. The level of expression of the 5-HT1d 
receptor is very low, the presence of a 5-HT1d autoreceptor in the DRN has been suggested, 
but not confirmed. 5-HT1e,f receptor mRNA has been identified in the brain, but little is 
known about the distribution and function, thus confirmation of a true physiological role for 
these  receptor  subtypes  is  still  lacking.  5-HT2a receptors are predominantly located 
throughout the cortex, caudate nucleus, nucleus accumbens, hippocampus, and basal 
ganglia. The expression of the 5-HT2b receptor is restricted to a few brain regions, 
particularly cerebellum, lateral septum, hypothalamus, and medial amygdala. Due to the 
lack of a selective 5-HT2c receptor ligand, the current knowledge concerning the distribution 
and function of this receptor is quite limited. 5-HT3 receptors are present in numerous brain 
regions, including the CA1 pyramidal cell layer in the hippocampus, the dorsal motor 
nucleus of the solitary tract, and the area postrema. Less is known about the expression of 
the 5-HT4-7 receptors. 5-HT6 receptor mRNA is located in the striatum, amygdala, nucleus 
accumbens, hippocampus, cortex, and olfactory tubercle. 5-HT7 binding sites were found in 
the limbic system and thalamocortical regions (reviewed in Saudou and Hen, 1994; Adell et 
al., 2002; Hoyer et al., 2002; Hannon and Hoyer, 2008). 
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The serotonergic system in sleep-wake regulation 
The discharge rate of serotonergic neurons in the DRN shows a distinct change in activity 
across  the  sleep-wake  states.  During  wakefulness  they  fire  at  a  regular  tonic  rate,  which  
decreases during NREM sleep and practically disappears during REM sleep (McGinty and 
Harper, 1976; Trulson and Jacobs, 1979). Extracellular serotonin levels are in 
correspondence with these changes in firing pattern (Portas and McCarley, 1994). Increases 
in serotonin levels or turnover in frontal cortex, hippocampus, hypothalamus, and brain 
stem are found during SD (Asikainen et al., 1997; Penalva et al., 2003). 
There is also evidence for a role of serotonin in the promotion of sleep and sleep 
homeostasis. Serotonin inhibits cholinergic BF neurons in vitro, and when injected into the 
BF it attenuates cortical arousal in vivo (Khateb et al., 1993; Cape and Jones, 1998). Non-
cholinergic neurons in the BF are also implicated in sleep–wake regulation (Hassani et al., 
2009), and they can be hyperpolarized by serotonin (Fort et al., 1998). Administration of the 
serotonin synthesis inhibitor p-chlorophenylalanine during SD suppresses rebound NREM 
sleep during recovery sleep (Sallanon et al., 1983), indicating that serotonergic influences 
during wakefulness could prepare the brain for sleep, and leading to the assumption that 
serotonin serves an important function in sleep pressure (Jouvet, 1999).  
The versatile role of serotonin in sleep-wake regulation is even more evident when we look 
at the effects of several receptor-specific manipulations on wakefulness, NREM, or REM 
sleep: 
5-HT1a and  5-HT1b receptor knockout mice showed increased amounts of REM sleep, also 
seen after systemic injections of 5-HT1a and 5-HT1b receptor antagonists in wild-type mice, 
while injections of 5-HT1a and 5-HT1b receptor agonists in wild-type mice and rats increased 
wakefulness, and reduced NREM and REM sleep (Boutrel et al.,  1999; Boutrel et al.,  2002; 
Monti, 2010). The 5-HT1 receptor family is inhibitory and, interestingly, manipulating the 5-
HT7 receptor, which is excitatory, shows the exact opposite effect on REM sleep. 5-HT7 
receptor knockout mice, as well as wild-type mice injected with a 5-HT7 receptor antagonist 
either systemically or directly into the DRN, display reduced amounts of REM sleep (Hedlund 
et al., 2005; Monti, 2010). The 5-HT2 receptor family may be more specifically involved in 
the regulation of NREM sleep. Ritanserin, a nonselective 5-HT2 receptor antagonist, 
increased NREM sleep in humans (Idzikowski et al., 1986) and in rats (Dugovic et al., 1989). 
Antagonizing the 5-HT2a receptor in mice increased NREM sleep, while 5-HT2a receptor 
knockout mice showed an increased amount of wakefulness during baseline and also 
showed  an  attenuated  NREM  delta  response  to  SD  (Popa  et  al.,  2005).  In  contrast,  
administration of a 5-HT2b receptor antagonist increased wakefulness and decreased NREM 
and REM sleep (Kantor et al., 2004). In the case of the 5-HT2c receptor, an early study found 
antagonists to promote NREM sleep (Sharpley et al., 1994), whereas more recent studies 
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showed that antagonizing the 5-HT2c receptor increased wakefulness and decreased NREM 
sleep (Kantor et al., 2005), and that 5-HT2c receptor knockout mice demonstrated increased 
amounts of wakefulness (Frank et al., 2002). 
1.4.3 Dopamine 
Dopaminergic system, projections, and innervation 
The major ascending dopaminergic pathway comprises several groups of neurons located in 
the mesencephalic tegmentum. Dopamine-containing neurons from the SN project to the 
dorsal  striatum, forming the nigrostriatal  pathway.  The VTA and SN jointly  give rise to the 
mesolimbic and mesocortical pathway innervating the BF, nucleus accumbens, septum, 
amygdala, hippocampus, olfactory tubercles, and frontal cortex. The tuberoinfundibular 
pathway consists of a group of short neurons projecting from the arcuate nucleus of the 
hypothalamus to the median eminence and pituitary gland. This pathway regulates the 
function of the pituitary gland (Moore and Bloom, 1978).  Lu et al (2006) recently discovered 
a group of wake active dopaminergic neurons in the vPAG matter, which projects to major 
components of the sleep–wake regulatory system including the BF cholinergic neurons. 
Neurons from the brainstem, hypothalamus, and BF innervate the dopaminergic system. 
These include neurons from the DRN/MRN, LC, LH, TMN, PPT/LDT, and BF. 
Synthesis and metabolism of dopamine 
Dopamine is synthesized from the aromatic amino acid precursor, tyrosine, which is taken 
up through the blood brain barrier by a transporter into the dopaminergic neurons. Tyrosine 
is converted by tyrosine hydroxylase to L-3,4-dihydroxyphenylalanine (L-DOPA), in the 
cytoplasm DOPA decarboxylase transforms L-DOPA to dopamine, which is subsequently 
stored in synaptic vesicles where the molecules are protected from catabolizing enzymes. 
Dopamine is released from these vesicles by exocytosis into the synaptic cleft, upon 
induction of depolarization and Ca2+ influx. The action of dopamine in the synapse is 
terminated by active re-uptake into the presynaptic nerve terminal by the specific dopamine 
transporter (DAT), or by extracellular metabolism (Fig. 7; Elsworth and Roth, 1997). 
Inside the neuron the main route of dopamine metabolism is oxidative deamination by 
MAO-B. MAO-B is the only metabolizing enzyme present in catecholaminergic neurons, 
although it is also found in glial cells and extracellularly (Agid et al., 1973; Elsworth and Roth, 
1997). Intracellularly, dopamine is converted to 3,4-dihydroxyphenylacetic acid (DOPAC) by 
activation of MAO-B. Extracellularly, DOPAC is then metabolized to homovanillic acid (HVA) 
by catechol-O-methyltransferase (COMT). Extracellular dopamine metabolism follows a 
different route: it is first metabolized by COMT to 3-methoxytyramine (3-MT) and then 
oxidized by MAO-B to form HVA (Westerink, 1985; Wood and Altar, 1988). COMT is found  
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Figure 7. Dopaminergic neurotransmission   
Tyrosine is converted to L-DOPA by tyrosine hydroxylase, which is transformed to dopamine by 
DOPA decarboxylase. Dopamine is stored in vesicles until released into the synaptic cleft, where it 
can bind to D1-like  or  D2-like receptors. The action of dopamine in the synaptic cleft can be 
terminated by active re-uptake by the DAT or by extracellular metabolism. Intracellular metabolism 
forms  DOPAC  via  the  monoamine  oxidase  route,  extracellularly  DOPAC  is  metabolized  to  HVA  by  
COMT. Extracellular dopamine is first metabolized to 3-MT by COMT, and then oxidized by MAO-B to 
form HVA. 3-MT, 3-methoxytyramine; COMT, catechol-O-methyltransferase; DA, dopamine; DAT, 
dopamine transporter; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; L-DOPA, L-
3,4-dihydroxyphenylalanine; MAO-B, monoamine oxidase B. 
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only outside dopaminergic neurons (Karhunen et al., 1995; Mannisto and Kaakkola, 1999), 
thus O-methylated metabolites provide markers of dopamine release. In the rat brain, 
DOPAC is the major metabolite, but the rate of HVA formation closely follows that of DOPAC 
(Westerink, 1979). In humans, however, the major brain metabolite is HVA (Elsworth and 
Roth, 1997). 
3-MT has been suggested to be the best marker of dopamine release in the brain; because 
COMT does not exist inside the dopaminergic neurons, all 3-MT found in the living brain is 
the product of dopamine that is released from the nerve endings (Rivett et al., 1983; 
Kaakkola  et  al.,  1987;  Karhunen  et  al.,  1995).  However,  the  metabolism  of  dopamine  by  
COMT is site-specific for the prefrontal cortex, where it accounts for 60% of dopamine 
metabolism  against  15%  in  the  rest  of  the  brain  (Karoum  et  al.,  1994).  The  major  role  of  
COMT in prefrontal cortex dopamine metabolism may be related to lower expression of DAT 
in this area and the resulting decreased capacity of re-uptake (Sesack et al., 1998). In other 
brain regions, including the striatum and amygdala, DOPAC and HVA might be better 
indicators of dopamine turnover than 3-MT (Yavich et al., 2007) 
Receptors 
Dopamine mediates its effects through two families of G protein-coupled receptors, defined 
on the basis of their pharmacological profile, function, and homology, i.e. D1-  and  D2-like 
receptors (Kebabian and Calne, 1979). The D1 and D5 receptors belong to the D1 family, and 
D2,  D3 and  D4 to  the  D2 family.  D1 receptors  are  coupled  to  stimulatory  G  proteins  that  
activate  adenylyl  cyclase,  leading  to  positive  regulation  of  cAMP  levels.  Their  stimulation  
results in the activation of the PKA cascade, which leads to an excitatory effect on the 
postsynaptic neuron. Conversely, the activation of the D2 receptor family mostly inhibits G 
proteins and thereby inhibits the corresponding neuron, be it pre- or postsynaptic (reviewed 
in Missale et al., 1998). 
The D1 receptor is the most prevalent dopamine receptor in the brain; it is mainly expressed 
in the striatum, nucleus accumbens, and olfactory tubercle, and at lower levels in the cortex, 
limbic system, thalamus, and hypothalamus (Le Moine et al., 1991).  Much less abundant is 
the  expression  of  the  D5 receptor, which is found in the olfactory tubercle, hippocampus, 
and hypothalamus, it is, though, widely expressed on cholinergic cells in the cerebral cortex, 
striatum, BF, and diencephalon (Berlanga et al., 2005).  
D2 receptors are expressed in the striatum, olfactory tubercle, and nucleus accumbens on 
GABAergic neurons (Le Moine and Bloch, 1995). D3 receptors are found primarily in limbic 
regions, i.e. the Isles of Calleja, nucleus accumbens, and olfactory tubercle. In the SN and 
VTA, D2 and D3 receptors are expressed by dopaminergic neurons, serving as autoreceptors 
(Meador-Woodruff et al., 1989; Weiner et al., 1991; Levant, 1997). The D4 receptor shows 
the lowest expression of all dopamine receptors with some expression in the basal ganglia 
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and moderately more expression in the frontal cortex, amygdale, and hypothalamus 
(O'Malley et al., 1992).  
The dopaminergic system in sleep-wake regulation   
Dopaminergic neurons have a low basal firing rate that is similar across sleep-wake states. 
However, two distinct firing patterns can be distinguished: a slow tonic spiking pattern and a 
burst  firing  or  phasic  pattern  (Grace  and  Bunney,  1984).  The  tonic  spiking  pattern  is  
characterized by trains of spikes that discharge at steady, but irregular, intervals, and it is 
the typical firing pattern of the majority of dopamine cells encountered in untreated, 
anaesthetized rats. The phasic pattern consists of consecutive spikes in a burst, displaying 
progressively decreasing amplitude and increasing duration. The phasic burst spike pattern 
leads to an enhanced release of dopamine (Grace and Bunney, 1984) and may be related to 
waking  (Rye  and  Jankovic,  2002;  Dahan  et  al.,  2007).  During  wakefulness  the  release  of  
dopamine is higher than during NREM sleep (Trulson, 1985; Lena et al., 2005). Recently, a 
group of wake active dopaminergic neurons that project to major components of the sleep–
wake regulatory system including the BF cholinergic neurons was indentified in the vPAG. 
After lesioning this region, a persistent increase in total sleep was observed (Lu et al., 
2006)). Drugs that inhibit dopamine re-uptake or stimulate dopamine release are associated 
with arousal (Nishino et al., 1998); in addition, DAT knockout mice show increased 
wakefulness compared to their wild type littermates (Wisor et al., 2001). Lesions of 
dopaminergic nuclei in the cat induce a state of behavioral unresponsiveness and immobility 
(Jones et al., 1973). Studies using dopamine-receptor-deficient mice, or animals injected 
with an antisense vector demonstrate that dopamine D1 and  D2 receptors facilitate 
behavioral arousal, while D3 receptors mediate the opposite effect. D1 and postsynaptic D2 
receptor agonists increase behavioral arousal and wakefulness, and decrease sleep 
(reviewed in Monti and Monti, 2007).  
Dopamine modulates Ach levels in the cortex by binding to dopamine receptors that are 
located directly on cholinergic neurons. Activation of the dopamine D1 receptor potentiates 
Ach release (Day and Fibiger,  1992;  Day and Fibiger,  1993).  A similar  stimulatory effect  on 
ACh release has been reported for the dopamine D5 receptor, which was recently found to 
be expressed on cholinergic BF neurons (Hersi et al., 2000; Berlanga et al., 2005). In 
contrast, the D2-like receptors attenuate ACh release (Stoof et al., 1987; Bertorelli and 
Consolo, 1990). In rat BF slices dopamine reduces inhibitory GABAergic transmission onto 
magnocellular BF neurons by activating presynaptic D1-like receptors (Momiyama and Sim, 
1996).  
  
34 
 
1.4.4 Histamine 
Histaminergic system, projections and innervation 
Histamine neurons are found exclusively in a small region in the posterior hypothalamus, 
the TMN (Panula et al., 1984; Watanabe et al., 1984). They send projections that innervate 
practically the entire brain (Panula et al., 1989). The highest density of innervations is found 
in the hypothalamus, BF, septum, and olfactory tubercle. Structures innervated by the 
dorsal ascending pathway, through the thalamus, show a lower density of histaminergic 
projections. The cortex and hippocampus are moderately innervated. In addition to these 
ascending projections the histaminergic system also sends descending projections to all of 
the ascending arousal systems; in particular the SN and VTA are strongly innervated (Kohler 
et al., 1985; Inagaki et al., 1988; Panula et al., 1989).   
The TMN receives input from the prefrontal/infralimbic cortex, septal regions, LC, 
DRN/MRN, LH, PPT/LDT, and VLPO (Ericson et al., 1989; Ericson et al., 1991; Chemelli et al., 
1999). 
Synthesis and metabolism of histamine 
Histamine is synthesized in the brain from L-histidine by histidine decarboxylase (HDC), and 
is subsequently transported into vesicles by the vesicular monoamine transporter. When 
released the only means to terminate its action is through metabolism to tele-
methylhistamine by the enzyme histamine N-methyltransferase, as no uptake system has 
been found (Fig. 8; reviewed in Haas et al., 2008).   
Receptors 
In the brain, histamine exerts its effect through three G protein-coupled receptors. 
Histamine receptors 1 and 2 (H1R and H2R) are found postsynaptically and induce an 
excitatory regulatory signal by activating the phospholipase C and the adenylyl cyclase 
pathways respectively. The histamine receptor 3 (H3R) inhibits the adenylyl cyclase 
pathway. It acts as an autoreceptor, reducing the release of histamine, while as a 
heteroreceptor it can regulate the release of several other neurotransmitters (Haas and 
Panula, 2003). H1R and H2R show a widespread expression in the brain; they are both 
expressed in the cortex, thalamus, VLPO, amygdala, septal nuclei, and cerebellum, and are 
colocalized in the hippocampus, LC, DRN/MRN, VTA, and SN. H1-receptors are also found in 
the BF, PPT/LDT, and nucleus accumbens (Bouthenet et al., 1988; Martinez-Mir et al., 1990; 
Traiffort et al., 1992; Vizuete et al., 1997). H3R are found in the cortex, nucleus accumbens, 
striatum, olfactory tubercles, and SN (Pollard et al., 1993). 
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Figure 8. Histaminergic neurotransmission  
L-histidine is converted by HDC to form histamine which is transported into vesicles by the vesicular 
monoamine transporter. When released, histamine can bind to H1, H2 or H3 receptors. Because no 
uptake system has been found, metabolism of histamine to tele-methylhistamine by the enzyme 
histamine N-methyltransferase is the only way to terminate its action.  
36 
 
The histaminergic system in sleep-wake regulation 
The observation that classical antihistamines have sedative effects led to the hypothesis 
that histamine plays a role in sleep-wake regulation. These classical antihistamines exert 
their actions by blocking the H1R, and today the evidence still points towards the 
involvement of the H1R, but not the H2R, in mediating arousal (Monti et al., 1986; Monti et 
al., 1990). 
Extracellular single-unit recordings of presumed histaminergic neurons which were 
performed  in  freely  behaving  cats  (Sakai  et  al.,  1990),  and  later  in  rats  (Steininger  et  al.,  
1999), revealed that the discharge activity of these neurons is highest during wakefulness, 
that their firing rate slows down during NREM sleep, and disappears almost completely 
during REM sleep. Evidence that activity of the histaminergic system depends on 
wakefulness  and  does  not  follow  a  strict  circadian  pattern,  came  from  a  c-Fos  staining  
experiment showing that histaminergic neurons are wake-active regardless of the time of 
day (Ko et al., 2003). More recently, identified histaminergic neurons were recorded in 
head-restrained non-anesthetized mice, showing that they are only active during 
wakefulness, showing the highest activity during attentive wakefulness, and are completely 
silent during NREM and REM sleep (Takahashi et al., 2006). 
Histamine release that was measured from microdialysis, push-pull technique, or CSF 
samples, was highest during the active period in freely behaving rats (Mochizuki et al., 1992; 
Prast et al., 1992), in rhesus monkeys (Prell et al., 1989), and in human children (Kiviranta et 
al.,  1994).  Strecker  et  al.  (2002)  showed  that  histamine  release  in  the  POAH  of  cats  was  
highest during wakefulness, lower during NREM sleep, and lowest during REM sleep. They 
did not observe any effect on extracellular histamine levels during a 6 h SD, suggesting that 
histamine does not relay information about sleep pressure to the sleep-promoting neurons 
of the VLPO. HDC knockout mice that are unable to synthesize neuronal histamine have 
difficulties in maintaining wakefulness in novel environments and show attenuated 
wakefulness due to shorter bout durations during the early part of the dark period 
(Parmentier et al., 2002). 
In vitro studies  demonstrated  that  histamine  excites  both  the  cholinergic  (Khateb  et  al.,  
1995)  and  non-cholinergic  neurons  of  the  BF  (Fort  et  al.,  1998),  predominantly  via  H1R.  
Infusions of histamine into the BF of freely moving rats showed that the BF indeed can play 
a  role  in  mediating  the  arousal  effect  of  histamine  (Ramesh  et  al.,  2004),  it  is,  however,  
unclear what the effects on the EEG of freely moving rats are and what effect antagonizing 
the actions of histamine in the BF will have on the amount of wakefulness.  
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1.5 The ascending arousal systems and their possible role in the sleep and 
wake regulation mediated by the BF 
During SD, the site-specific accumulation of adenosine inhibits cholinergic BF neurons, 
which results in an increased sleep pressure (Porkka-Heiskanen et al., 1997; Porkka-
Heiskanen et al., 2000; Kalinchuk et al., 2008). This raises the question how the animals are 
able to stay awake during as much as a 6 h SD. In fact, during the first three hours of SD, the 
activity of both BF and cortical neurons is increased, which may be required to maintain 
vigilance  (Kostin  et  al.,  2010;  Vyazovskiy  et  al.,  2009).  One  explanation  could  be  that  the  
ascending arousal systems increase their activity to counteract the effect of sleep pressure. 
If this is the case, the BF, considering that it is an important ventral extrathalamic relay of 
the ascending arousal systems to the cortex, might play an important role in mediating the 
increased activity of the ascending arousal systems during SD.  
All  the  ascending  arousal  systems  have  a  higher  discharge  rate  during  wakefulness  as  
compared to sleep and they all project to the BF. Even though some studies found increases 
in the level or turnover of serotonin in frontal cortex, hippocampus, hypothalamus, and 
brain stem during SD (Asikainen et al., 1997; Penalva et al., 2003), in human subjects brain 
dopamine levels were increased after SD (Volkow et al., 2008), and in the POAH of the cat 
histamine did not increase during SD (Strecker et al., 2002), nothing is known about the 
effects of SD on the levels of these monoamines in the BF. In addition, no studies have been 
performed to examine to what extent the ascending arousal systems are involved in sleep 
homeostasis mediated by the BF. 
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2 AIMS AND HYPOTHESES OF THE STUDY 
 
The main aim of this thesis was to explore the role of the ascending arousal systems in the 
regulation of sleep, wakefulness, and cortical activation mediated by the BF. Do the 
ascending arousal systems increase their activity during SD? Does this increased activity 
counteract  the  sleep-promoting  effects  of  SD?  Does  their  activity  during  prolonged  
wakefulness induce a homeostatic sleep response? Are these actions mediated by 
cholinergic neurons? 
 
Specific questions: 
I  OREXIN: 
It is known that reduced levels of orexin lead to sleep fragmentation and narcolepsy, 
but does orexin overexpression lead to vigilance state consolidation, and what effect 
does it have on sleep homeostasis? 
 
II SEROTONIN & DOPAMINE: 
SD leads to a site-specific increase in extracellular adenosine that inhibits cholinergic 
BF neurons. During the first hours of SD the activity of BF neurons increases, 
suggesting increased activity of the ascending arousal systems to counteract this 
inhibitory effect. Are serotonin and dopamine systems affected by SD, and are their 
extracellular levels increased in the BF after SD? 
 
III & IV HISTAMINE: 
Many studies showed that histamine release is increased during the active/waking 
period.  Is  this  because  histamine  release  is  under  circadian  control,  or  does  it  
depend on vigilance state? Do histamine levels in the BF (study III), and/or in the 
TMN (study IV) correlate with behavioral state?  
Does SD increase histamine release in the BF? And do elevated histamine levels in 
the BF induce wakefulness, associated with cortical high frequency theta activation, 
followed by increased sleep intensity (study III)? 
To what extent do BF cholinergic neurons mediate the effects of histamine on 
cortical activation (study III)? 
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3 MATERIALS AND METHODS 
 
Details of the materials and methods can be found in the original publications (I-IV). Only 
those procedures in which the author was personally involved are listed in this chapter. 
The Ethics Committee for Animal Experiments at the University of Helsinki and the 
provincial  government  of  Southern  Finland  approved  all  experiments,  which  were  carried  
out in accordance with the laws of Finland and the European Union. We made every effort 
to minimize the number of animals used and their suffering.   
 
3.1 Animals 
Mice were used in the studies that required genetic manipulation; they were also used for 
microdialysis studies after the method had been set up for mice. Han-Wistar rats were used 
for microdialysis studies because of their docile nature, before the method had been 
modified to suit mice.  
 
Mice 
Study I 
Five- to seven-month-old male Balb/c x DBA/2 (CD2) wild type or transgenic (overexpressing 
the hPPO gene) mice were individually housed in a 12-h light-dark cycle (n wild type = 11; n 
transgenic = 14). Standard rodent pellets and water were provided ad libitum. Before 
surgery, mice were habituated to handling for a 3- to 4-week period. 
Study IV 
Male C57BL/6J mice (10 weeks old; n = 5) were kept individually under a reversed 12-h light-
dark cycle. Standard food pellets and water were available ad libitum.  The mice were 
habituated to handling for 2 weeks before surgery.  
 
Rats (Studies II & III) 
Male Han-Wistar rats aged three to four months (300-400 g) were individually housed under 
constant temperature in a 12-h light-dark cycle (n study II = 16; n study III = 25). Food and 
water were provided ad libitum. The animals were habituated to handling beginning at least 
four days before surgery.  
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3.2 Surgery (Studies I, II, III, IV)  
Under general anesthesia, the animals were placed in a stereotaxic device. Two gold-coated 
screws were fitted into the skull for frontoparietal epidural bipolar recording of the EEG. To 
record the EMG, two silver wire electrodes were inserted into the neck musculature. 
In studies II & III a unilateral guide cannula for the microdialysis probe (CMA 11 Guide) was 
placed 3 mm above the BF area. 
In study IV a unilateral guide cannula (CMA 7 Guide) was implanted into the posterior part 
of the hypothalamus 1 mm above the target site.  
Finally, the guide cannula, screw electrodes and supporting screws were secured in place 
with acrylic dental cement. After recovery and adaptation to the recording conditions (at 
least one week), a two- or three-day recording was taken from each animal to ensure that 
they had fully adapted.   
 
3.3 EEG/EMG recording and analysis (Studies I, II, III, and IV) 
The  EEG  and  EMG  signals  were  amplified  (gain  5  or  10  K),  filtered  (high  pass:  0.3  Hz;  low  
pass 100 Hz), and sampled at at least 200 Hz. EEG recordings were manually scored in two- 
or four-second  epochs for wakefulness, NREM sleep and REM sleep in the Spike2 program 
using the script Sleepscore v1.01.  
In order to examine the vigilance state distribution during our experiments, the vigilance 
states  were  scored  according  to  standard  criteria.  Wakefulness  was  scored  for  low-
amplitude desynchronized EEG activity in combination with activity in the EMG. NREM sleep 
was determined by high-amplitude delta (0.5-4 Hz) waves in the EEG and low-amplitude or 
absent EMG. REM sleep was identified by regular theta (5–9 Hz) activity in the EEG and low 
or absent EMG activity. In study II wakefulness and NREM were scored semi-automatically in 
30 s epochs using custom-made scripts (Stenberg et al., 2003), while REM sleep was scored 
manually.  
To score low and high EMG-activity wakefulness, the maximum EMG amplitude was 
determined for every 24-h file. Epochs were scored as low EMG-activity wakefulness when 
the  amplitude  of  the  EMG  in  the  entire  epoch  did  not  rise  above  25%  of  the  maximum  
amplitude. High EMG-activity wakefulness was scored when the EMG amplitude rose above 
25% of the maximum amplitude. Brief awakenings were scored for brief periods of 
wakefulness lasting no more than 16 s. Epochs containing artifacts were excluded from 
further analysis. 
EEG power spectra were calculated within the 0.5-50 Hz frequency range by fast Fourier 
transform (FFT = 256, Hanning window, 0.5 or 1Hz resolution).  
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3.4 Video monitoring (Studies I and IV) 
To check for possible symptoms of narcolepsy, such as cataplexy, in the orexin-
overexpressing mice (study I), as has been reported for mice with a disrupted orexin system 
(Mochizuki et al., 2004), we continuously monitored the mice with standard miniature 
infrared surveillance video cameras throughout the third and fourth recording week. The 
video and EMG/EEG recordings showed no signs of  sudden attacks of  inactivity,  or  loss  of  
muscle tone together with prominent EEG theta activity.  
We also used video monitoring to quantify the motor activity of mice whilst measuring the 
extracellular histamine levels in the TMN and recording EEG/EMG (study IV).  
 
3.5 Control day (Studies I, II, III, and IV) 
The control day served as a reference to which subsequent EEG recordings and, if 
applicable, microdialysis samples, obtained during the SD days or during drug perfusion 
experiments (see below), were compared. This day also served to observe and, if needed, 
control for any diurnal effects. During the control day the animals were allowed to sleep and 
wake undisturbed. In the studies that included microdialysis the probes were continuously 
perfused with artificial CSF (aCSF) at a rate of 1 ?l/min. 
 
3.6 Sleep deprivation (Studies I, II, and III) 
To study the effects of increased homeostatic sleep pressure, we deprived the animals of 
sleep by gentle handling (Franken et al., 1991), a method in which we introduced novel 
objects into the home cage whenever the animals appeared to be sleepy. This method 
stimulates active wakefulness and results in increased sleep pressure. The increased sleep 
pressure increases sleep propensity and leads to a recovery sleep, which is characterized by 
an increase in the amount, consolidation (as measured by brief awakenings or sleep 
fragmentation), and intensity (as defined by increased NREM delta (0.5 - 4 Hz) power) of the 
subsequent NREM sleep.  
 
3.7 Murine multiple sleep latency test (MMSLT; Study I) 
The MMSLT was adapted from the MSLT, which was developed in 1977 and is commonly 
used as a diagnostic tool to test sleepiness in humans (Carskadon and Dement, 1977). This 
test measures the sleep latency and is based on the idea that when sleep pressure is high 
the latency to fall asleep is low. The MMSLT protocol was developed by Veasey et al. (2004), 
and was slightly adapted for this study (I). Sleep latencies were measured during four 
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consecutive 20 min nap opportunities during baseline conditions and following 6 h of SD; 
prior to each nap opportunity the mice were kept awake for 10 minutes by gentle handling. 
 
3.8 In vivo microdialysis and reversed microdialysis (Studies II, III, and IV) 
We used in vivo microdialysis to examine the concentration of several neurotransmitters in 
the extracellular space of the BF of rats, and the TMN of mice. This technique is based on 
passive diffusion of small molecules across a semi-permeable membrane according to their 
concentration gradient. It allows us to continuously sample a specific brain area for multiple 
days  in  freely  moving  animals.  When  this  is  combined  with  EEG/EMG  recording,  we  can  
correlate the concentrations of specific neurotransmitters to vigilance state. In addition, by 
using reversed microdialysis we can apply drugs to a very specific area and study the effects 
simultaneously. 
Microdialysis probes (Rats: CMA 11, membrane length 2 mm; Mice: CMA 7, membrane 
length 1 mm) were inserted through their guide cannulae 18-24 h before the first 
experiment. Perfusion of aCSF by a microdialysis syringe pump (flow 1 µl/min), started 
either  directly  (study  III  &  IV)  or  just  after  lights-on  on  the  control  or  SD  day  (study  II).  
Samples were collected at 20 or 30 min intervals continuously. In study II we stopped aCSF 
perfusion half an hour before lights-off, and disconnected the animals from the 
microdialysis  tubing.  For  studies  III  and  IV  we  adapted  the  system  to  keep  the  animals  
constantly connected to the microdialysis tubing, and consequently were able to 
continuously collect samples using an automated sample collection system over several 
days. We performed an in vivo recovery experiment to validate the stability of the recovery 
of the microdialysis probes over several days. We compared the maximum concentrations 
of histamine in 30-min samples on the control day and after five days of continuous 
perfusion and found no significant differences (data not shown). Samples were stored at 
?80 C until assayed. EEG and EMG were recorded continuously. 
3.8.1 Reversed microdialysis (Study III) 
In study III we used reversed microdialysis to perfuse either histamine at three different 
concentrations (100, 500 or 1000 µM), or pyrilamine (10 mM), a H1R antagonist, into the BF. 
The drug perfusions were carried out following the control day for up to five days after the 
control day. All drug solutions were prepared in aCSF. The three-hour drug perfusions were 
preceded by a three-hour baseline period of aCSF perfusion (same-day baseline). 
To examine the arousal effect of histamine, histamine was perfused during the light period 
(sleep period for rats) between three and six hours after lights-on. During the dark period 
(active period for rats), the H1R antagonist was perfused from three to six hours after lights-
off, to examine its sedative effects. After drug perfusion, the perfusion medium was 
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reverted back to aCSF while the perfusion continued non-stop.  The perfusions of different 
drugs were performed at least 24 h apart in a counterbalanced design. 
3.9 Unilateral local cholinergic lesion experiments (Study III) 
In order to find out whether or not the cholinergic neurons in the BF are responsible for 
mediating histamine-induced cortical arousal we used the immunotoxin 192IgG-saporin to 
induce unilateral local cholinergic lesions (study III). This method was modified from 
Kalinchuk et al. (2008). 192IgG is a monoclonal antibody that binds to the p75 nerve growth 
factor receptor that is selectively expressed on cholinergic BF neurons. When linked to 
saporin, the newly formed 192IgG-saporin complex acts as a selective immunotoxin, 
destroying cholinergic BF neurons (Book et al., 1992; Heckers et al., 1994).  
We used a modified microdialysis probe, with the membrane tip cut off and connected to a 
10-?l Hamilton syringe, to inject the 192IgG-saporin (0.23 ?g/?l) locally during the surgery 
for EEG/EMG electrode placement and microdialysis guide cannula implantation. To reach a 
total injection volume of 1 ?l, 192IgG-saporin was injected into the HDB/SI/MCPO at a flow 
rate of 0.1 ?l/min for 10 minutes. To minimize the chance of pulling out the injected 
solution while removing the modified probe, we left it in place for five minutes before 
taking it out.  
Two  weeks  after  the  lesion,  at  which  time  local  cholinergic  lesions  show  optimal  cell  
degeneration, the control day and drug perfusion experiments were repeated as described 
previously. For histamine perfusions, we used only the highest dose (i.e.1000 ?M).  
3.9.1 ChAT Immunohistochemistry (Study III) 
After the experiments we verified the local cholinergic lesions by choline acetyltransferase 
(ChAT) immunohistochemistry. The ChAT antibody binds to ChAT, the enzyme responsible 
for  the  synthesis  of  Ach  from  acetyl-coenzyme  A  and  choline,  which  is  only  expressed  in  
cholinergic neurons. 
We transcardially perfused the rats under deep anesthesia with a 0.9% saline followed by 
4% paraformaldehyde in 0.1 M phosphate buffer (PBS, pH 7.4). We then removed the brains 
and postfixed them overnight in the same paraformaldehyde solution, after which they 
were submerged in a 30% sucrose solution at 4°C for four days for cryoprotection. After the 
brains sank, they were frozen and stored at -80°C. All the way through the BF area, coronal 
sections (40 µm) were cut on a freezing microtome and collected into PBS for 
immunohistochemical staining for ChAT. The sections were washed in PBS, endogenous 
peroxidase activity was blocked by incubation with 0.3% hydrogen peroxide in PBS for 30 
min at room temperature, after which the sections were treated with blocking solutions 
(0.5% Triton-X in PBS for 2 h; 3% donkey serum in PBS for 1 h) and incubated overnight at 
4°C with a rabbit anti-ChAT primary antibody (1:1000). The next day, the sections were 
incubated with the secondary antibody (biotinylated donkey anti-rabbit IgG 1:300) for two 
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hours at room temperature and treated with avidin–biotin complex. Diaminobenzidine 
tetrahydrochloride was used for visualization. After staining, the sections were mounted on 
microscope slides and coverslipped with Eukitt quick-hardening mounting medium. We 
counted the ChAT-positive cells unilaterally in three sections (interval 200 µm) per rat using 
a  light  microscope  at  a  10x  magnification;  a  4x  magnification  was  used  to  determine  the  
outline of the BF. The cell counts of these three sections were averaged and compared 
between the lesion and control groups.  
 
3.10 Histological verification of probe locations (Studies II, III, and IV)  
After  the  experiments,  the  animals  received  a  lethal  dose  of  pentobarbital.  To  verify  the  
probe locations, ink was injected through a modified microdialysis probe inserted into the 
guide cannula. The brains were then removed, frozen on dry ice, and stored at ?80 °C.  
Sections (20 ?m) were cut on a freezing microtome, stained with Toluidine Blue, and visually 
inspected under a light microscope. Only data from animals with probe tips located within 
the  limits  of  the  BF  region  (studies  II&III;  HDB,  MCPO,  SI)  or  the  posterior  hypothalamus  
(study IV; TMN) were included in the analysis.   
 
3.11 HPLC (Study II) 
The  concentrations  of  5-HIAA,  DOPAC  and  HVA  were  determined  from  the  microdialysis  samples  
using high-performance liquid chromatography (HPLC) combined with electrochemical detection. 
The  system  had  a  detection  limit  of  approximately  5  nM.  The  HPLC  setup  consisted  of  a  Waters  
717Plus  autosampler,  a  Waters  510  pump,  a  Symmetry  C18  5µm  column,  and  a  Concorde  
electrochemical detector, set to a potential of 800mV using a Ag/AgCl reference electrode. Waters 
Millennium 32 software was used for system control and data collection/processing. The HPLC 
system was used in an isocratic mode at a 1 ml/min flow rate. The mobile phase consisted of 50 mM 
H3PO4, 50 mM citric acid, 0.15 mM EDTA, 2 mM octanesulphonic acid sodium salt, and 5% methanol, 
pH 2.5.  
 
3.12 Statistical analyses 
A global overview of the statistics used in studies I-IV is reported here, for more detailed 
information please consult the original publications.   
All  values  are  shown  as  mean  ±  standard  error  of  mean  (SEM).  Statistical  analyses  were  
performed using SigmaStat 3.1. P < 0.05 was deemed significant. 
For correlation analysis the Pearson Product Moment Correlation was used. When simple 
comparisons between two groups of animals were made we used unpaired t-tests, when 
comparisons  were  made  between  two  time  points  within  the  same  group  of  animals  we  
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used paired t-tests. For more complicated analyses including several time-points and or 
multiple factors we used one-way or two-way repeated measures analysis of variance 
(ANOVA). When a control period was available, ANOVAs with multiple comparisons versus 
control group were used.  All repeated-measures ANOVAs were followed by Holm-Sidak 
post hoc tests. In situations when the normality assumption failed, an ANOVA on ranks (a 
corresponding non-parametric test) was used, with Dunn’s method as post hoc test. 
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4 RESULTS AND DISCUSSION 
 
Table 1. Main results 
Study Main methods Main results 
 
I 
(mice) 
Overexpression of the 
human prepro-orexin 
transgene (hPPO) 
Increased orexin A levels and decreased OX2R expression in 
the hypothalamus of hPPO overexpressing mice 
 EEG/EMG recording 
baseline 
Reduced amount of REM sleep in hPPO overexpressing mice 
 EEG/EMG recording  
6 h sleep deprivation 
Increased slow wave intrusion in the wakefulness-specific 
EEG of hPPO overexpressing mice 
 
II 
(rats) 
Microdialysis and 
EEG/EMG recording 
6 h sleep deprivation  
Gradual increase in extracellular serotonin and dopamine 
metabolite levels, reaching a plateau during the third hour of 
sleep deprivation  
 
Gradual decrease in metabolite levels during recovery sleep 
 
III 
(rats) 
Microdialysis and 
EEG/EMG recording 
baseline day 24 h in the BF  
Extracellular histamine levels in the BF correlate with the 
amount of wakefulness independent of the time of day  
 Microdialysis and 
EEG/EMG recording 
6 h sleep deprivation 
Immediate increase in extracellular histamine during sleep 
deprivation  
Immediate decrease during recovery sleep  
 
 
 
Histamine perfusion into 
the BF by reversed 
microdialysis  
Increase in wakefulness and high theta EEG frequencies 
associated with attentive wakefulness 
 
Decrease in NREM sleep and delta EEG frequencies 
associated with sleep and drowsiness   
 
No NREM delta rebound after  histamine perfusion   
 Histamine receptor 1 
antagonist perfusion into 
the BF by reversed 
microdialysis 
Decrease in wakefulness and high theta frequencies in 
wakefulness-specific EEG 
 
Increase in light NREM sleep with slightly lower than normal 
delta power  
 Histamine or histamine 
receptor 1 antagonist 
perfusion after lesion of 
the cholinergic neurons in 
the BF  
No significant effects 
 
IV  
(mice) 
Microdialysis and 
EEG/EMG recording 
baseline day 24 h in the 
TMN 
Extracellular histamine levels in the TMN correlate with the 
amount of wakefulness independent of the time of day 
 
Histamine release  in the TMN correlates positively with high-
theta and gamma EEG frequencies, associated with attentive 
wakefulness  
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4.1 The effect of overexpression of orexin on sleep-wake regulation (Study I) 
In study I we characterized the sleep-wake regulation of transgenic mice overexpressing the 
human prepro-orexin (hPPO) transgene under control of its endogenous promoter.  
 
4.1.1 hPPO overexpression reduced the amount of REM 
sleep during baseline recordings 
We found increased levels of the hPPO transgene mRNA and orexin A in the hypothalamus 
of transgenic mice. Transgene overexpression decreased OX2R expression in their 
hypothalami, but we observed no effect on hypothalamic OX1R expression and OX1R/OX2R 
levels in the BF, cortex or hippocampus.  
As expected, because cataplexy is a symptom of narcolepsy associated with decreased, and 
not increased, orexinergic transmission, the video recording in combination with EEG/EMG 
recording did not show any signs of cataplexy.  
During the control day we did not find any statistically signi?cant differences between the 
genotypes in the overall percentage of time spent in each vigilance state, in bout durations, 
the number of state transitions (NREM to wake or REM to wake transitions), or the number 
of brief awakenings (I; Table 1). Thus, we did not find evidence of vigilance state 
fragmentation or consolidation in the orexin-overexpressing mice. We did find minor but 
statistically signi?cant differences in the percentage of time spent in each vigilance state per 
hour during the light-dark transition period. In addition, at several time points throughout 
the light-dark cycle transgenic mice spent less time in REM sleep (I; Fig.4)  
Our  observations  with  regard  to  the  amount  of  REM  sleep  showed  a  slight  decrease  at  
several  time  points.  These  results  are  consistent  with  those  of  Mieda  et  al.  (2004),  who  
showed a decrease in the amount of REM sleep during the daytime in mice with a ?-actin/ 
cytomegalovirus hybrid promoter to drive orexin overexpression. Both REM and NREM 
sleep were decreased in rodents after ICV injections of orexin into the lateral ventricle 
(Piper et al., 2000), or after its perfusion into the TMN during the light period (Huang et al., 
2001).  In  contrast,  orexin  knockout  mice  showed  increased  amounts  of  REM  sleep  during  
the dark period (Chemelli et al., 1999; Willie et al., 2003). However, Mochizuki et al. (2004) 
recently reported that orexin knockout mice exhibit normal amounts of wakefulness, NREM, 
and REM sleep; they attribute the increased REM sleep observed in orexin knockout mice 
(Chemelli et al., 1999; Willie et al., 2003) to episodes of cataplexy, since the previous studies 
did not separate those from REM sleep (Mochizuki et al., 2004). It is obvious from the work 
of Willie et al. (2003) that the OX1R might be involved in the regulation of REM sleep. In our 
study, overexpression of orexin led to decreased REM sleep and, in contrast to the OX2R, 
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the OX1R expression was not affected, which points to the possibility that the observed 
decrease in REM sleep might be caused be increased activation of the OX1R by orexin A. 
 
4.1.2 Increased slow wave intrusions in hPPO 
overexpressing mice during SD 
When comparing transgenic and wild-type mice during SD, we found that SD was effective 
in keeping the animals of both genotypes awake, as mice were awake on average 93.7±1.7% 
of the time, although the transgenic mice did sleep a bit more (wild-type: 95.6±1.5%, n = 6; 
transgenic:  92.9±2.5%,  n  =  9).  Compared  to  the  wild-type,  transgenic  mice  also  showed  a  
higher  intrusion  of  slow  waves  during  wakefulness  as  shown  by  an  increase  in  low  delta  
power (1 Hz). The fact that slow waves are more prominently present in the waking EEG 
during SD of orexin overexpressing mice might lead us to believe that the transgenic mice 
have a less stable EEG. However, the transgenic mice also showed slightly more sleep during 
the SD, and because there was also no increase in fragmentation of vigilance states it is also 
possible that the transgenic animals were sleepier than the wild-type controls. On the other 
hand, if the transgenic mice were indeed sleepier, we would have expected to find a shorter 
sleep latency in the MMSLT test, which was not the case.  
During recovery sleep the amounts of NREM and REM sleep in both groups increased 
compared to baseline (Table 2), thus both groups demonstrated a recovery sleep response. 
Both genotypes showed the same amount of NREM sleep, number of brief awakenings, and 
latency to NREM sleep (as investigated by the MMSLT). The amount of REM sleep, though, 
was reduced in transgenic mice compared to wild-type controls at several time points 
during both the light and dark periods (I; Fig. 5e), as well as overall during the recovery sleep 
in the light period (I; Table 2). However, when recovery REM sleep during recovery sleep 
was normalized to the control day within each individual animal, no reduction in REM sleep 
remained, demonstrating that the transgenic mice have a normal REM sleep response to SD. 
During recovery sleep, NREM sleep intensity, as defined by increased NREM EEG delta (1–4 
Hz) power, was attenuated in the transgenic mice compared to wild-type controls. In the 
EEG power spectra after SD the NREM delta power increased in both genotypes (I; Fig. 5d); 
this increase, though, was attenuated in the low delta range (1-2 Hz) in the transgenic mice 
during  the  first  two  hours  of  recovery  sleep.  It  is  not  surprising  that  the  orexin-
overexpressing mice exhibited an attenuation in the intensity of recovery sleep, because 
they showed a higher intrusion of slow delta waves in the waking EEG during SD; part of the 
sleep pressure had thus already been released during the SD, resulting in a lower sleep 
pressure at the start of recovery sleep. 
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4.1.3 Limitations of the hPPO overexpressing mouse 
strain 
Characterization and quantification of the EEG of several inbred mouse strains revealed that 
EEG patterns demonstrate a high degree of heritability, and that distinct differences in 
NREM  delta  power  exist  between  the  Balb/c  and  DBA/2  strains  (Franken  et  al.,  1998).  
Additionally, BALB/c mice exhibit a weak diurnal rhythm (Valatx and Bugat, 1974). 
Consequently, it is possible that the mixed genetic background of the CD2 hybrid strain 
could at least partly be responsible for the differences in the distribution of vigilance states 
and in the EEG power found in this study (Franken et al., 2001). 
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4.2 Extracellular serotonin and dopamine metabolites increase in the BF 
during SD (study II) 
In study II we measured the effect of increased sleep pressure on serotonin and dopamine 
turnover in the BF, as measured by their major metabolites using in vivo microdialysis in 
rats.  
 
4.2.1 Increased serotonin metabolite levels in the BF 
during SD 
During SD the extracellular levels of 5-HIAA in the BF progressively increased with every 
hour  (II;  Fig.  3a).  After  SD,  the  recovery  sleep  induced  a  steady  decrease  of  the  5-HIAA  
concentration back towards baseline level. During the first 3 hours of the lights-on period on 
the control day, we observed a slight decrease in the BF 5-HIAA levels, after which the levels 
stabilized. Since extracellular 5-HIAA levels reflect serotonin turnover, at least when the re-
uptake mechanism is intact (Rollema et al., 1996; Stenfors et al., 1999), the increase in 5-
HIAA levels reflects a slow and steady increase of serotonin turnover in the BF during SD.  
Serotonin is thought to stimulate wakefulness, because serotonergic neurons are most 
active and extracellular serotonin levels are highest during this vigilance state (McGinty and 
Harper, 1976; Trulson and Jacobs, 1979; Portas and McCarley, 1994; Penalva et al., 2003). 
Indeed, on the control day we found higher levels of extracellular 5-HIAA during the parts of 
the light period corresponding to periods with higher amounts of wakefulness. In addition, 
we found that prolonged wakefulness induced by SD resulted in an increase in serotonin 
turnover.  
On the other hand, there is also evidence for a role of serotonin in the promotion of sleep 
and in sleep homeostasis. Serotonin inhibits cholinergic BF neurons in vitro, and when 
injected into the BF it attenuates cortical arousal in vivo (Khateb  et  al.,  1993;  Cape  and  
Jones, 1998). Non-cholinergic neurons in the BF are also implicated in sleep–wake 
regulation (Hassani et al., 2009), and they can be hyperpolarized by serotonin (Fort et al., 
1998). Administration of the serotonin synthesis inhibitor p-chlorophenylalanine during SD 
suppresses rebound NREM sleep during recovery sleep (Sallanon et al., 1983), leading to the 
conclusion that serotonin serves an important function in sleep pressure (Jouvet, 1999).  
The versatile role of serotonin in sleep-wake regulation is even more evident when we look 
at the effects of several receptor-specific manipulations on wakefulness, NREM, or REM 
sleep, which is addressed in the literature review. 
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Because of this multifaceted role of the serotonergic system, being more active during 
wakefulness and being able to stimulate both wakefulness and sleep, serotonin might be 
able to provide the brain with a signal for both the duration and the intensity of 
wakefulness, which would make the serotonergic system an important player in the 
homeostatic regulation of sleep. By selectively expressing certain receptors in specific areas 
of the brain, serotonin could stimulate wakefulness in the cortex, while it could attenuate 
cortical arousal by specifically inhibiting the BF. Indeed, the expression pattern of 
serotonergic receptors throughout the brain is quite diverse, with some receptors being 
widely expressed, whereas others have a very limited distribution (Saudou and Hen, 1994; 
Adell et al., 2002; Hoyer et al., 2002; Hannon and Hoyer, 2008).  
In our results, the build-up of serotonin turnover during SD is slow and gradual; it resembles 
the way extracellular adenosine builds up during SD (Porkka-Heiskanen et al., 1997; 
Kalinchuk et al., 2011). Both adenosine and serotonin inhibit cholinergic neurons in the BF. 
Taken together with the previous findings we hypothesize that serotonin may be partly 
responsible for increases in sleep pressure by adding to the increase of homeostatic sleep 
pressure in the BF in a similar way as adenosine does. 
 
4.2.2 Increased dopamine metabolite levels in the BF 
during SD 
SD induced a gradual increase of extracellular DOPAC levels, reaching a plateau during the 
third hour. Until the second hour of recovery sleep the DOPAC levels did not decrease, but 
then quickly decreased towards baseline levels (II; Fig. 3b). Similarly to DOPAC levels, 
extracellular HVA levels increased gradually during SD, also reaching a plateau during the 
third hour of SD and lasting until the second hour of recovery sleep when a decrease 
towards the baseline level started (II; Fig. 3c). HVA levels did not completely return to 
baseline during the 3-h recovery period (II; Fig. 3c). The extracellular levels of both 
dopamine metabolites decreased during the first four hours on the control day, after which 
the levels stabilized.  
Because dopamine is metabolized to DOPAC intracellularly or to 3-MT extracellularly, and 
both  are  transformed  into  HVA  as  the  final  metabolite  (Ashcroft,  1969;  Miyamoto  et  al.,  
1991), DOPAC and HVA are reliable indicators of dopamine turnover (Elsworth and Roth, 
1997; Yavich et al., 2007). 
Very few studies have looked at dopamine release in freely behaving animals. A study using 
voltametry showed an increase in dopamine release in the caudate nucleus of the cat during 
wakefulness (Trulson, 1985). Léna et al. (2005) showed that also in the nucleus accumbens 
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and in the medial prefrontal cortex of the rat dopamine release is higher during wakefulness 
as compared to NREM sleep. In our study we showed that in the BF extracellular dopamine 
metabolite levels were higher in the beginning of the control day, when the animals spent 
more time awake. In addition, our results showed an increase in dopamine turnover in the 
BF during SD.   
The dopamine turnover during SD increased gradually, comparable to the way sleep 
pressure increases as reflected by the adenosine levels in the BF. The slow build-up of 
dopamine metabolites reaching a plateau in the third hour of SD also mimics the increase in 
neuronal firing observed during SD in the BF (Kostin et al., 2010) and the cortex (Vyazovskiy 
et al., 2009) of the rat. Because dopamine has an excitatory effect on cholinergic neurons, 
this  suggests  that  increased  dopamine  turnover  in  the  BF  could  assist  in  increasing  the  
neuronal firing rate in both BF and cortex, promoting cortical arousal, and may counteract 
the inhibiting effects of sleep factors during SD.  
 
4.2.3 Effects of SD on BF corticosterone levels 
Because of a possible interaction between glucocorticoids and monoaminergic 
neurotransmission, and a possible occurrence of mild stress associated with SD that could 
lead to an activation of the hypothalamic–pituitary–adrenal (HPA) axis and thus increase 
corticosterone levels, we also measured corticosterone from the microdialysate. 
Extracellular corticosterone levels in the BF on the control day showed low levels during the 
morning and an increase at the end of the lights-on period, corresponding with the 
expected  circadian  peak  (II;  Fig.  4).  No  increase  in  serotonin  and  dopamine  turnover  was  
found on the control day, therefore an interaction between corticosterone increase and 
serotonin/dopamine turnover was not apparent.  
The corticosterone levels remained at baseline level during the first three hours of SD, 
increasing only during the last three hours. Immediately from the start of recovery sleep the 
corticosterone levels returned back to the pre-SD baseline, hereby omitting the diurnal 
peak. In contrast, serotonin/dopamine turnover remained at or just below the maximum 
from the third hour of SD until the second hour of recovery sleep, again showing no 
influence of the corticosterone levels.  
Comparing the individual maximum values of the corticosterone levels during the lights-on 
period on the control day to those of the SD period indicated that corticosterone 
concentrations during SD did not exceed the normal diurnal peak levels. Thus indicating that 
our method of SD by “gentle handling” did not induce substantial stress. Our results are in 
accordance  with  other  studies  that  have  shown  SD  to  have  only  a  mild  or  transient  
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activating effect on the HPA axis in rats (Tobler et al., 1983; Meerlo et al., 2002; Penalva et 
al., 2003).  
The increase seen in corticosterone levels after the third hour of SD might reflect a need of 
the waking system for additional arousal-inducing substances to sustain vigilance, because 
dopamine turnover reaches its highest intensity at the third hour of SD, and at the same 
time also the neuronal activity has reached its maximum (seen in BF and cortical neurons 
induced by SD; Vyazovskiy et al., 2009; Kostin et al., 2010).  
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4.3 The role of histamine in sleep-wake regulation (Studies III&IV) 
In studies III & IV we examined the role of histamine in sleep-wake regulation in the BF of 
rats (study III) and in the TMN of mice (study IV). 
 
4.3.1 Histamine levels in the BF and the TMN correlate 
with wakefulness 
To investigate whether histamine release in the BF correlates with vigilance state, we 
compared the histamine levels in microdialysis samples from the rat BF and the mouse TMN 
to the amount of wakefulness in the corresponding 30-min bin. We found a strong positive 
correlation between histamine release in the BF and wakefulness, which was unaffected by 
the  light-dark  cycle  (III;  Fig.  2B  &  C).  In  the  mouse  TMN  we  found  that  histamine  release  
shows the highest correlation with wakefulness and that is correlates to a lesser extent with 
motor activity (IV; Table 3). A similar correlation between cortical histamine levels and 
wakefulness  was  previously  found  (Chu  et  al.,  2004).   In  addition,  Strecker  et  al.  (2002)  
found that histamine release in the POAH of the cat is highest during wakefulness. 
During the light period (sleep period for rodents) the histamine levels in the BF and the TMN 
were generally low and interspersed with increases during periods of waking (III; Fig. 2C, IV; 
Fig. 5A & B). This suggests that the potential circadian component in the regulation of brain 
histamine levels is overruled by vigilance state; in other words, during waking, histamine 
levels increase regardless of the time of day.  
We found that histamine release positively correlated with high theta (7.5-9.5 Hz) and 
gamma (above 35 Hz) frequencies in the EEG recording, which are associated with active 
and attentive wakefulness. The extracellular histamine levels did not correlate with EEG 
markers of quiet wakefulness (4-7 Hz). During wakefulness, histamine release correlated 
inversely with the EEG delta range (1-4 Hz) that is associated with sleep (IV; Fig. 5C). These 
results are in line with previous findings showing that the activity of histaminergic neurons is 
highest during attentive wakefulness (Takahashi et al., 2006). 
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4.3.2 Histamine in the BF induces attentive wakefulness 
and increases cortical activity, but is not affected by 
increased sleep pressure, and does not induce a recovery 
sleep 
In study III we found that histamine perfusion increased wakefulness and reduced NREM 
sleep (III; Fig. 3), as was already observed by Ramesh et al. (2004). When we examined the 
EEG power spectra, we found that histamine perfusion in the BF specifically increases 
attentive wakefulness. Histamine activates the cortex by increasing frequencies that 
associate with active and attentive wakefulness (high theta; 7-9 Hz), and decreasing 
frequencies that associate with quiet wakefulness (low theta; 4-7 Hz), drowsiness during 
wakefulness, or deep sleep during NREM sleep (delta; 0.5-4 Hz, III; Fig. 4). These results are 
very similar to the frequencies which we found to correlate with natural histamine release 
in study IV, and agree with the findings of Anaclet et al. (2009), who showed that histamine 
promotes wakefulness without increasing motor activity in a wheel running task. When we 
looked at the EEG power during histamine perfusion separately for low and high EMG-
activity wakefulness, we found that in both cases the high theta frequency was enriched (III; 
Fig. 5A & B), and also that the distribution of low and high EMG-activity wakefulness during 
histamine perfusion did not change. Thus, histamine seems to specifically promote attentive 
wakefulness and not motor activity. 
The theta-enriched cortical activation which is mediated by histamine in the BF does not 
lead to increased sleep pressure. Because the BF is a key site for the regulation of cortical 
activation and sleep homeostasis, and is also one of the main targets of histaminergic 
neurons (Panula et al., 1989), we expected to observe an effect of SD-induced increased 
sleep pressure on extracellular histamine levels in the BF. In addition, we expected 
histamine perfusion to lead to increased sleep pressure, due to increased activity of the BF. 
Contrary to our expectations, we did not observe a progressive increase in extracellular 
histamine concentrations during the 6-h SD period. Instead, the increase in histamine 
concentration started immediately at the initiation of the SD, and remained stable 
throughout the entire SD period (III; Fig. 2A). Because the build-up of sleep pressure during 
the SD period is gradual, the stable and immediate increase in the amount of extracellular 
histamine levels indicates that sleep pressure does not affect histamine release in the BF. It 
has already been shown that sleep pressure does not influence histamine levels in the POAH 
of the cat (Strecker et al., 2002). Together, these studies strongly indicate that histamine 
release is not regulated by sleep pressure, and does not transfer information about sleep 
pressure. 
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In addition, we did not find a NREM delta rebound after histamine perfusion. Considering 
the substantial increase in attentive wakefulness which is induced by histamine perfusion in 
the BF, and the extensive and long-lasting decrease in NREM delta power during the 
perfusion and its persistence during the first 3-h recovery period for the higher 
concentrations, this was rather surprising. We also did not find an increase in any other 
measures  of  sleep  intensity  after  the  histamine  perfusions  (III;  Fig.  6),  leading  to  the  
conclusion that histamine-induced prolonged wakefulness is not followed by the classic 
homeostatic response. Previous work also showed no increase in the amount of sleep after 
BF histamine perfusion (Ramesh et al., 2004) or after i.p. administration of H3R antagonists 
(Parmentier  et  al.,  2007),  but  these  studies  did  not  examine  the  NREM  EEG  delta  power,  
which is important because  the increase of NREM EEG delta power is the key characteristic 
of rebound sleep.   
Previous work from our lab shows that several glutamate agonists stimulate the BF and all 
induce prolonged wakefulness. Only NMDA perfusion increased high theta activity during 
this extended period of wakefulness, and only after NMDA perfusion a homeostatic 
response, measured by NREM delta power, was observed, suggesting an association 
between the homeostatic response and the high level of cortical activation (Wigren et al., 
2007). In the present study we found that histamine perfusion led to increased high theta 
activity during wakefulness, but did not observe a homeostatic response. Histamine and 
NMDA activate the BF in different ways; histamine depolarizes BF cholinergic neurons and 
increases their tonic firing (Khateb et al., 1995), while NMDA promotes rhythmic bursting 
(Khateb et al., 1997). This different way of activating the BF could result in a different build-
up of extracellular adenosine and sleep pressure and might be responsible for the lack of 
NREM delta rebound after histamine perfusion. It is also possible that the increase in theta 
power (20-30%) was not high enough, or that the increase in the amount of wakefulness 
was not sufficient to elicit a homeostatic response, although the increase in wakefulness 
was comparable to that seen after NMDA perfusion. 
 
4.3.3 The cholinergic BF is a key site for histamine to 
promote cortical activation and wakefulness. 
In order to study the importance of the BF in relaying the activity of the histaminergic 
system to the cortex we decided to use a H1R antagonist (pyrilamine). By using an 
antagonist  we  merely  blocked  the  action  of  physiological  histamine  levels  in  the  BF,  and  
thus were able to get a better impression of the importance of histaminergic activation of 
the BF in cortical arousal under physiological conditions. When we antagonized the H1R in 
the BF, we found a radical decrease in wakefulness (III; Fig. 7a), which was even more 
surprising because the perfusion was performed unilaterally and reached only one of the 
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major  brain  regions  that  can  activate  the  cortex.  In  addition,  the  high  theta  range  in  the  
wakefulness-specific EEG recording, which is associated with attentive wakefulness, was 
decreased after antagonist perfusion (III; Fig. 7b), showing the importance of histaminergic 
activation of the BF in maintaining a high level of cortical activation. Ramesh et al. (2004) 
found that histamine perfusion into the thalamus had no effect on wakefulness or NREM 
sleep. Together, these results suggest that of the several different ascending and 
descending pathways which histamine can employ to activate the cortex, the BF is the key 
site for histamine to promote cortical activation and wakefulness (III; Fig. 9).  
The next question we addressed was whether indeed the cholinergic neurons of the BF 
were involved in mediating the arousal effects of histamine. We know that in guinea pig BF 
slices cholinergic neurons are activated mainly through H1R (Khateb et al., 1995), and that 
histamine perfusion in the BF of freely moving rats increased ACh release in the cortex 
(Cecchi et al., 2001). In contrast, the actions of histamine on GABAergic and glutamatergic 
neurons in the cortically projecting part of the BF are poorly characterized, and histamine 
can excite GABAergic neurons in the adjacent MS/DBB that projects to the hippocampus via 
both H1R and H2R (Xu et al., 2004). We therefore used a unilateral local BF cholinergic 
lesion approach (Kalinchuk et al., 2008) to investigate the effect of abolishing cholinergic BF 
neurons on histamine-induced cortical activation. Intraparenchymal injections of the 
immunotoxin 192IgG-saporin selectively lesion BF cholinergic neurons without affecting the 
number of parvalbumin- and GAD-immunopositive neurons (Pizzo et al., 1999; Kalinchuk et 
al., 2008; Kaur et al., 2008). Following the cholinergic lesions we repeated the histamine and 
H1R antagonist perfusions, and now these perfusions had no significant effect on vigilance 
state (III; Fig. 8).  
Because the method spares the other neuronal types in the BF and because the lesion is 
local, thereby sparing, for instance, the septo-hippocampal cholinergic system (Berntson et 
al., 2002), the lack of significant effects on vigilance state after drug perfusion demonstrates 
that indeed the cholinergic BF neurons mediate histamine-induced cortical arousal.  
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5 CONCLUSIONS 
 
The main conclusions of this thesis can be summarized as follows: 
We found that, although during wakefulness all studied ascending arousal systems increase 
their transmitter release in the BF, not all of them seem to be involved in the regulation of 
sleep homeostasis. The orexinergic, serotonergic, and dopaminergic systems show signs 
that lead us to believe that they are involved in the regulation of sleep pressure, or at least 
that they are affected by sleep homeostasis. The orexinergic system appears capable of 
influencing sleep homeostasis, and the dopaminergic and serotonergic systems seem to 
either counteract or add to sleep pressure. On the other hand, the histaminergic system is 
neither affected by, nor able to manipulate sleep pressure in the BF and thus shows no signs 
of being involved in sleep homeostasis mediated by the BF.  
In addition, we revealed that theta-enriched cortical arousal mediated by activation of the 
BF via the ascending arousal systems does not necessarily lead to a homeostatic sleep 
response. This response appears to depend on the type of activation that is induced in the 
BF, and is most likely receptor and thus neurotransmitter specific.  
Finally, we established that histamine activates the cholinergic BF via histamine 1 receptors 
and that this activation is essential in sustaining a high level of cortical activation, indicating 
the importance of the BF in mediating the wake-promoting effects of histamine. Reduced 
activation of the cholinergic BF by histamine may be important in initiating and maintaining 
NREM sleep. 
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6 FUTURE DIRECTIONS 
 
In this thesis the role of some of the ascending arousal systems in the regulation of sleep, 
wakefulness,  and  cortical  activation  mediated  by  the  BF  was  elucidated.  I  have  looked  at  
certain aspects of several ascending arousal systems and have been able to answer some of 
the questions at hand; however, many questions remain to be clarified. 
Are increased orexin levels indeed responsible for the increased slow delta wave intrusions 
into the waking EEG during SD, found in study I? Because the neural mechanisms behind 
these intrusions which could be seen as dissociative states with sleep leaking into 
wakefulness, are unknown, and because orexin is involved in vigilance state control by 
playing a crucial role in the “flip-flop” switch, orexin could be an excellent candidate to be 
involved in this sleep leakage. 
We showed that some transmitter systems are affected by increased sleep pressure in the 
BF,  but  we  still  need  to  explore  which  of  these  are  involved  in  increasing  BF  activity,  and  
which  type  of  neurons  they  activate  most.  Does  this  increased  activity  lead  to  increased  
adenosine concentrations in the BF, and a subsequent homeostatic sleep response? It also 
remains unclear what kind of activation is necessary to induce a NREM delta response 
mediated by the BF. 
According  to  our  results,  the  BF  might  be  the  main  route  for  histamine  to  promote  
wakefulness; this, however, should be further investigated, for instance by stimulating the 
TMN whilst antagonizing the BF, or after inducing a cholinergic lesion.  
The results from this thesis might contribute to the development of new sleep or wake 
medication. A histamine receptor 3 agonist could be a potent sleep inducing substance, 
because it can inhibit histaminergic transmission. Clinical trials are already underway. 
However, the results presented here indicate that inhibiting the histaminergic pathway 
results in light sleep, and might, therefore, not lead to the desired effect.  
Histamine receptor 3 antagonists, that increase the histaminergic transmission, are tested 
for the treatment of excessive daytime sleepiness in narcolepsy patients and for treatment 
of ADHD. The results in this thesis show that histamine is very effective in increasing 
attentive wakefulness, which is beneficial for both groups of patients. Some caution should 
be  taken,  because  the  effect  of  histamine  might  last  for  many  hours  and  thus  could  
negatively influence the subsequent sleep.      
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